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ABSTRACT
THE ROLE OF SYSTEM XC- IN COGNITION: THE IMPORTANCE OF
NEURON-ASTROCYTE SIGNALING

Evan M. Hess, B.S.
Marquette University, 2020

The biological basis of human intelligence is largely a mystery, but likely
required evolutionary adaptations to achieve the information processing capacity
needed to expand the complexity of cognition among species. The link between
evolutionary expansion of signaling complexity in the brain and cognition has
largely focused on neuronal mechanisms, in part because information processing
has historically been attributed to these cells. However, astrocytes are emerging
as a second type of brain cell that is capable of processing information due to
their capacity to release glutamate and, thereby, regulate neural circuits. Hence,
a modern question is whether astrocytes contributed to the signaling complexity
required for sophisticated forms of cognition. The glutamate release mechanism
system xc- (Sxc) is the ideal mechanism to investigate this question because it is
evolutionarily novel to vertebrate species and it is expressed by astrocytes. The
central hypothesis tested herein is that Sxc increased the complexity of
glutamate signaling and is required for behavior requiring complex cognition. To
test, a genetically modified rat with Sxc activity eliminated was generated (MSxc
rats). Phenotyping revealed that loss of Sxc activity produced changes in
behavior that reflect diminished cognition or top-down processing including
impaired reversal learning, set-shifting, and attentional allocation. Remarkably,
loss of Sxc did not impact central regulation of metabolism, Pavlovian
conditioning, instrumental conditioning, locomotor activity, and novel-object
recognition. Additionally, Sxc is integral to the regulation of neural networks. In
the nucleus accumbens, we found that a loss of Sxc altered synaptic strength in
a circuit specific manner. Further, we found that Sxc-mediated glutamate release
is regulated by presynaptic (the neuropeptide PACAP), postsynaptic
(endocannabinoid) and hormonal (glucocorticoids) signaling mechanisms.
Further interrogation of Sxc regulation by PACAP revealed that this neuropeptide
acts on both neurons and astrocytes to facilitate bidirectional neuron-astrocyte
signaling between Sxc and extrasynaptic NMDA receptors. The in vivo relevance
of this mechanism is established by our findings that PACAP microinjected into
the nucleus accumbens attenuates cocaine-primed reinstatement, and the
regulation of this behavior requires both Sxc and NMDA receptors. These
findings support the possibility that future therapeutics could restore cognition by
targeting astrocytes.
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CHAPTER I
THE BURDEN OF COGNITIVE DISORDERS AND THEIR CELLULAR AND
MOLECULAR ORGINS

The Burden of Cognitive Disorders Represents an Unmet Medical Need
Neuroscience research has the potential to greatly reduce the burden of
neurological disorders by discovering new molecular targets to replace the
current therapeutic strategies that have failed to reduce disease burden. As of
2016, the World Health Organization (WHO) has established neurological
disorders, including mental and behavioral disorders, as one of the leading
causes of disease burden worldwide and in the United States as measured by
disability-adjusted life years (DALYs) (Geneva, 2018). DALYs are a measure of
the number of years of life lost to premature mortality and the years of life lost
due to disability in the given population (Figure 1-1A). Of these neurological
disorders, mental and behavioral disorders such as substance abuse, anxiety,
depression, and schizophrenia contribute the greatest disease burden (Figure 11B). The high proportion of DALYs for mental and behavioral disorders is
suggestive of a major medical need that is unmet by the current therapeutic
strategies used. Given that the unmet medical need of CNS disorders has not
decreased despite a more advanced understanding of the brain, a paradigm shift
in both research focus and therapeutic strategy may be required.
Arguably, the most efficient strategy to reduce disease burden will involve
researching and therapeutically targeting the most debilitating and common
underlying symptoms that contribute to the etiology of mental and behavioral
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Figure 1-1: WHO 2016 percent of total disease-adjusted life years (DALYs) lost to major
diseases in the United States of America. A, Data was tabulated from the 2016 WHO
estimates for the top 10 diseases with the greatest life burden. B, Data depicts proportion of
DALYs under the mental/behavioral disorder category. Substance abuse disorders include
opioid and alcohol use.

disorders. This ideology is supported by a recent change in research philosophy
established by the National Institute of Mental Health called Research Domain
Criteria (RDoC). One of the principle aims of RDoC is to identify the fundamental
and discrete components underlying multiple disorders that can be readily
studied by researchers with the goal of more efficiently reducing disease burden
(Cuthbert & Insel, 2013). This is in contrast to canonical approaches where
research focus was aimed towards studying the underlying basis of multi-faceted
diseases such as depression or schizophrenia which are exceptionally difficult to
model in rodents. Given this, RDoC has the potential to transform neuroscience
research and therapeutic strategies through revealing the neurobiological basis
of discrete brain functions (e.g., cognitive control) which could lead to improved
patient care for multiple diseases that share a particular symptom.
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Substance abuse, depression, anxiety, and schizophrenia all share a
debilitating common symptom, cognitive dysfunction (Millan et al., 2012).
Cognition represents a complex array of discrete forms of brain function ranging
from simple forms of learning and memory to much more complex forms that are
often collectively referred to as executive functions such as self-control and
selective attention (Diamond, 2013; MacLean, 2016; Ralph, Jefferies, Patterson,
& Rogers, 2017). As such, cognition is a type of brain function that is highly
amendable to an RDoC approach in that researchers can focus on discrete
cognitive processes (e.g. self-control) that may benefit multiple disorders. Thus, if
we can understand the cellular and molecular mechanisms underlying discrete
cognitive processes in the brain, we can develop improved therapies and
significantly reduce the disease burden of cognitive disorders. Unfortunately,
uncovering the basis of cognition is complicated by the brain being an
exceptionally complex biological system which has stymied the emergence of
successful therapeutics (Millan et al., 2012).
Establishing the Importance of Glutamate and Astrocytes to Cognition
Our incomplete understanding of the human brain and more specifically
intercellular communication is a fundamental barrier in the development of
disease modifying therapeutics that are needed to mitigate the impact of
cognitive disorders (Sundstrom, 2007). Central to this endeavor is thoroughly
revealing the molecular, cellular, and structural components of intercellular
communication which collectively dictate how information is transferred from cell
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to cell within neural circuits; especially since neurotransmitter receptors are the
most common target for CNS therapeutics (Raiteri, 2006).
Due to the mathematical complexity created by billions of cells
communicating across trillions of synapses, the analysis of nervous system
evolution may provide useful insights into the organizational and signaling
principles of the vertebrate brain that engendered enhanced cognitive abilities
which may allow us to refine our therapeutic targets (Bosch et al., 2017; Emes et
al., 2008; Herculano-Houzel, 2012; Hoshiba, Wada, & Hayashi-Takagi, 2017;
Tang, Nyengaard, De Groot, & Gundersen, 2001). At the molecular level,
phylogenetic studies have detected several classical neurotransmitters present in
vertebrates such as glutamate, gamma-aminobutyric acid (GABA), histamine,
and monoamines in at least some of the basal metazoan clades which suggests
each of these molecules were essential components during the evolution of the
nervous system (Moroz, 2009, 2015; Moroz & Kohn, 2016; J. F. Ryan & Chiodin,
2015; J. F. Ryan et al., 2013). However, the amino acid neurotransmitters
glutamate and GABA are unique relative to histamine and monoamines. First,
these neurotransmitters often directly activate ligand-gated ion channels to
produce rapid changes in the excitation state of neurons. Second, glutamate and
GABA are expressed in most if not all neural circuits in the brain. Because of this,
glutamate and GABA are often modeled as the primary excitatory and inhibitory
neurotransmitters, respectively, and are involved in most forms of information
transfer in vertebrate nervous systems (Goetz, Arslan, Wisden, & Wulff, 2007;
Traynelis et al., 2010). In further support, disrupted glutamate signaling has been
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linked to cognitive dysfunction seen in schizophrenia, bipolar disorder,
depression and substance abuse and has therefore driven research focus
towards therapies that target glutamate receptors and transporters (Dauvermann,
Lee, & Dawson, 2017; Kalivas, 2009; C.-T. Li, Yang, & Lin, 2019). Thus, as it
relates to intercellular communication, information transfer and cognitive
processing, understanding the forces influencing glutamate signaling will be
essential to any endeavor seeking to resolve how and why cognitive disorders
emerge.
Evolutionary adaptations to nervous systems enabling increased
computational capacity of cellular networks and improved energy efficiency were
likely crucial to phylogenetic gains in cognitive ability (Bosch et al., 2017; Emes
et al., 2008; Niven & Laughlin, 2008; T. J. Ryan & Grant, 2009; Yu & Yu, 2017).
For example, a key evolutionary event in the expansion of intercellular signaling
in complex nervous systems was the recruitment of astrocytes to the processing,
integration, and storage of information in conjunction with providing needed
metabolic and structural support to neural networks (Alvarellos-Gonzalez, Pazos,
& Porto-Pazos, 2012; Min, Santello, & Nevian, 2012; Oberheim, Wang, Goldman,
& Nedergaard, 2006; Porto-Pazos et al., 2011). To achieve this, astrocytes are
capable of monitoring the activity of thousands to millions of synapses due to the
expression of most of the traditional neurotransmitter receptors and are capable
of integrating this information and communicating back to neurons through the
release of a variety of neuroactive substances (Bormann & Kettenmann, 1988;
Cahoy et al., 2008; Clarke & Barres, 2013; Glaum, Holzwarth, & Miller, 1990;
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Grybko, Sharma, & Vijayaraghavan, 2010; Navarrete & Araque, 2010; Oberheim
et al., 2006; Ogata & Kosaka, 2002; Pruss, Akeson, Racke, & Wilburn, 1991;
Shen & Yakel, 2012; von Blankenfeld & Kettenmann, 1991; Zanassi, Paolillo,
Montecucco, Avvedimento, & Schinelli, 1999). Importantly, astrocytes can
leverage glutamate as a signaling molecule to regulate neural networks while
also using it as a metabolic substrate to provide energy for high intensity
information processing. As such, glutamatergic signaling by astrocytes should be
seriously considered for their potential role in cognition.
Intriguingly, the phylogenetic increases in the complexity of central
nervous systems was accompanied by dramatic changes in astrocytes or glial
cells. For example, C. elegans expresses 0.2 glia for every neuron, whereas the
brain of H. sapiens has 1.4 glia for every neuron (Nedergaard, Ransom, &
Goldman, 2003). As a result, glia are the most abundant cell type in the human
brain (Herculano-Houzel, 2012). Remarkably, the evolution of astrocytes
occurred on a pace rapid enough that astrocytes can even be distinguished
between closely related species. For example, human cortical astrocytes are
reported to be 2.6-fold larger in diameter, extend 10-fold more primary
processes, and propagate intracellular signals (i.e., Ca2+ waves) four-fold faster
than rodent astrocytes. The human brain even has anatomically-defined
subclasses of astrocytes that are not found in rodents (Oberheim et al., 2009).
Hence, there is a fundamental need to understand how glutamate signaling
between neurons and astrocytes regulates the function of complex brains

7
(Alvarellos-Gonzalez et al., 2012; Min & Nevian, 2012; Oberheim et al., 2009;
Oberheim et al., 2006).
Over the past few decades, astrocytes have been found to contribute to
virtually every aspect of brain function, including neural development, synapse
formation, synapse pruning, synaptic plasticity, glutamate signaling, gating of
neural circuits for excellent reviews (Allen & Barres, 2005; Christopherson et al.,
2005; Haydon, Blendy, Moss, & Rob Jackson, 2009; Oberheim et al., 2006;
Papouin, Dunphy, Tolman, Foley, & Haydon, 2017; Perea, Sur, & Araque, 2014;
Porto-Pazos et al., 2011; Poskanzer & Yuste, 2011). Despite the broad functional
role of these cells, the potential for these cells to underlie cognition is a new
concept (Santello, Toni, & Volterra, 2019). The following sections will discuss the
functional relationships between astrocytes and neurons and how they rely on
glutamate for information transfer and how glutamate signaling from these cells
may impact the information processing capacity of neural circuits and
consequently impact cognition. Figure 1-2 represents some of the key
components of glutamate signaling within the glutamate synapse. This model is
meant to set the framework for what is known about glutamatergic signaling and
set the context for the experiments and data presented in the following chapters.
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Figure 1-2: Model for glutamate homeostasis within the tri-partite synapse. The cellular
components of the tri-partite are illustrated by the pre- and post-synaptic terminals and the
peri-synaptic astrocytic process. Key glutamate enzymes include glutaminase (GA) which
converts glutamine to glutamate within the pre-synaptic terminal, and glutamine synthetase
(GS) which converts glutamate to glutamine within astrocytes. Glutamate-cysteine ligase
(GCL) dimerizes glutamate and cysteine (reduced cystine) and undergoes an additional
enzymatic step via glutathione synthetase (GTS) to produce glutathione. Glutamate can also
be converted to α-ketoglutarate and re-enter the TCA cycle to produce ATP. Vesicular release
mediated by the SNARE complex, excitatory amino acid transporters (EAATs), and the
cystine-glutamate antiporter system xc- (Sxc) help maintain intra and extracellular glutamate
balance. Glutamate receptors such as AMPAR, NMDAR, and metabotropic glutamate
(mGluR) receptors exist within the synaptic and extrasynaptic space and are activated by
different sources of glutamate. Neurotrophic factors (NTFs) are released by astrocytes and
signal through their receptors (NTFRs) on neurons to facilitate glutamate receptor expression.
The foundation for the structural basis of the tripartite synapse is the extracellular matrix
(ECM). The volume of space between astrocytes and neurons are dictated by tenascins,
which is critical for the diffusion of glutamate and its ability to access extrasynaptic receptors.
The synapse is stabilized by neurexins and neuroligins which bridge the pre-synaptic SNARE
complex and the postsynaptic density (PSD-95) to ensure efficient chemo-electrical transfer of
information. This is further stabilized by proteins released by astrocytes such as hevin.

A Brief Overview of Glutamate Metabolism in the Tripartite
Glutamate may have evolved into the primary excitatory neurotransmitter
in the brain because it is highly abundant and couples key cellular processes
such as energy and antioxidant production needed for the efficient expansion of
nervous systems (Moroz & Kohn, 2016).
Astrocytes serve as the major source of metabolically derived glutamate
in the brain and have an efficient network of transporters and enzymes to tightly
regulate glutamate concentration, metabolism, as well as providing glutamate
precursors to neurons (Schousboe, Scafidi, Bak, Waagepetersen, & McKenna,
2014). The canonical glutamate synthesis pathway within the astrocyte involves
the synthesis of pyruvate from glycolysis which enters the tri-carboxylic acid
(TCA) cycle to produce α-ketoglutarate (α-KG). Other than continuing through the
cycle, α-KG can undergo reversible transamination catalyzed by glutamate
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dehydrogenase to produce glutamate. Glutamate can then be converted into
glutamine via the astrocyte specific enzyme glutamine synthetase. Glutamine is
subsequently exported from the cell via system N transport (SN1) where it enters
the extrasynaptic space awaiting import into presynaptic nerve terminals via
system A transport (SAT). The accumulated glutamine within the presynaptic
terminal is converted back into glutamate via glutaminase which can then be
packaged into vesicles and released into the synaptic cleft. To complete the
cycle, released glutamate is taken up by sodium dependent astrocytic glutamate
transporters such as GLT-1. Studies predict that about 85% of the reaccumulated glutamate within the astrocytic cytosol is converted back into
glutamine to be released again, with the rest undergoing deamination back into
α-KG which re-enters the TCA cycle to be recycled for further ATP production
(Rothman, De Feyter, de Graaf, Mason, & Behar, 2011). This outline of the
glutamate-glutamine cycle highlights two major roles of glutamate in the
synergistic relationship between neurons and astrocytes within the peri-synaptic
space; glutamate is traded as a metabolic molecule in addition to acting as a
signaling molecule.
The conversion of glutamate back into α-KG to re-enter the TCA cycle and
drive ATP production demonstrates its role as a key metabolic currency. The
ratio of glutamate that is shunted back through the TCA cycle to be oxidized for
ATP production is dynamically regulated depending on the state of the external
milieu and internal energy demand of the astrocyte. For example, exogenously
applied glutamate to astrocyte cultures is converted back into α-KG which in a
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stepwise manner produces malate then pyruvate which can re-enter the TCA
cycle as acetyl-CoA (McKenna, 2013). The rate of this phenomenon is
determined by the extracellular concentration of glutamate. In support, models
estimate glutamate to have a peak concentration of 1.5 mM following quantal
release within the synapse with transient extracellular glutamate at about 10 μM
(Matsui, Jahr, & Rubio, 2005). When glutamate is exogenously applied within this
range (100 to 500 μM) the astrocyte responds by shuttling a larger proportion of
glutamate through this oxidative pathway; an increase from about 15.3% at
baseline to 42.7%. As a result, less glutamate is converted back into glutamine in
astrocytes which reduces available glutamine for neurons from 85% at baseline
to 57% (McKenna, Sonnewald, Huang, Stevenson, & Zielke, 1996). The use of
glutamate as an energy source is theorized to result from the intense energy
demand within astrocytes. Specifically, the increase in extracellular glutamate
following phasic neuronal release requires uptake of glutamate via sodiumdependent astrocyte transporters e.g. GLT-1. This produces a significant sodium
gradient that requires the utilization of ATP to be corrected via sodium/potassium
ATPase (McKenna, 2013).
Models of glutamate release and clearance demonstrate how efficient
glutamate signaling is in that it has the potential to produce more energy than it
spends. In support, one quanta of glutamate amounts to about 4000 molecules
(Riveros, Fiedler, Lagos, Munoz, & Orrego, 1986) with one quanta being
released per action potential according to estimates in hippocampal neurons (T.
A. Ryan & Smith, 1995). This would require 12000 Na+ ions to be extruded
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following uptake via GLT-1 which amounts to 4000 Na+/K+ ATPase cycles and an
equivalent number of ATP molecules required to correct the Na+ gradient. Yet,
the net energy yield for the uptake and oxidation of 1 glutamate molecule is
about 23-26 ATP; theoretically about 160 glutamate molecules would be
sufficient to pay for the uptake of 4000 molecules (McKenna, 2013). These
estimates predict glutamate uptake and oxidation is providing a net excess of
ATP. Hence, neuron-astrocyte glutamate signaling is highly efficient and
produces a net excess of energy which can fuel the processing power of neural
networks required for cognition.
The abundance of glutamate may also be attributed to its use as a
substrate for the brain anti-oxidant glutathione (Yelamanchi et al., 2016).
Importantly, glutamate signaling can pose serious challenges to a nervous
system due to the metabolic demand it creates and the risk of excitotoxicity
(Lewerenz & Maher, 2015). In order to counteract this risk, neural cells adapted a
mechanism to utilize excess glutamate in conjunction with cysteine and glycine to
produce glutathione. Glutathione is synthesized within astrocytes via a series of
enzymatic reactions. First, the enzyme glutamate-cysteine ligase (GCL)
catalyzes the linking of glutamate and cysteine. Next, glutamate-cysteine is
linked to glycine via the actions of glutathione synthetase (GS) to produce
glutathione (Bridges, Lutgen, Lobner, & Baker, 2012). Because of the
involvement of glutamate in the citric acid cycle and biosynthesis of the
antioxidant glutathione, the selection of glutamate as the primary excitatory
neurotransmitter may have helped address the balance of excitotoxicity and
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oxidative stress by efficiently coupling excitatory signaling with energy production
and oxidative stress defense mechanisms.
Given these metabolic mechanisms, glutamate was an ideal molecule to
evolve into the single most abundant amino acid and the primary excitatory
signal in the vertebrate brain (Abeles, 1991; Braitenberg, Schüz, & Braitenberg,
1998; Kasthuri et al., 2015; Schousboe, 1981).
Glutamate Signaling in the Synaptic Cleft
The glutamate synapse represents the most common functional domain in
the brain, with estimates placing glutamate at nearly 95% of cortical synapses
(Kasthuri et al., 2015). The typical glutamate synapse is comprised of a presynaptic terminal, a postsynaptic terminal, and a perisynaptic astrocytic process
(as depicted Figure 1-2). This section will consider the factors that influence each
of these components and how they work together in order to efficiently transfer
information.
The release of glutamate from the presynaptic neuron occurs in the active
zone, a specialized region in axonal terminals or boutons containing hundreds of
proteins that collectively create a highly organized matrix enabling calciumdependent release of glutamate (Gronborg et al., 2010; Korber & Kuner, 2016;
Ribrault, Sekimoto, & Triller, 2011). Ca2+-dependent release involves a series of
highly orchestrated events that results in the formation of a fusion pore that can
be shared between the plasma membrane and the membranes of synaptic
vesicles containing high mM levels of glutamate (Burger et al., 1989; Shupliakov,
Brodin, Cullheim, Ottersen, & Storm-Mathisen, 1992). The release probability of

14
glutamate is influenced by Ca2+ influx into the presynaptic terminal through
voltage-gated calcium channels (VGCCs) which are triggered by the arrival of
action potentials (Branco & Staras, 2009). Ca2+ is received by synaptotagmin,
which are a class of trans-vesicular membrane associated proteins belonging to
the SNARE complex that drive vesicular docking, fusion, and release of
glutamate (Südhof, 2013).
There are multiple presynaptic glutamate receptors that may enable
regulation over the pattern and amount of presynaptic glutamate release that
impact Ca2+ dynamics in the terminal. First, the metabotropic glutamate receptors
(mGluRs) which belong to the G-protein coupled receptor (GPCR) family can
impact pre-synaptic glutamate release. There are three major classes of
mGluRs; group 1,2, and 3 which have varying cellular expression and
localization. The predominant mGluRs expressed in the pre-synaptic terminal
belong to group 2 and 3. These groups signal through Gi/Go which inhibit
adenylate cyclase and consequently ion channels such as VGCCs (Niswender &
Conn, 2010). For example, application of a group 2 mGluR agonist to
hippocampal slices reduced pre-synaptic Ca2+ influx which produced a reduction
in mEPSC frequency at the mossy fiber-CA3 synapse (Kamiya & Ozawa, 1999).
Ionotropic glutamate receptors may also contribute to pre-synaptic
regulation of synaptic glutamate release. The two most common ionotropic
glutamate receptors are n-methyl d-aspartate receptors (NMDARs) and α-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). NMDARs
and AMPARs are characterized as tetramers, containing four subunits with a
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central ion pore. Their principle function is to conduct ionic currents in order to
rapidly depolarize neurons or trigger intracellular signaling cascades (Traynelis et
al., 2010). In the presynaptic compartment, NMDARs are largely involved in
positively influencing neurotransmitter release. Their effect can either be direct or
indirect in that activation can directly increase Ca2+ influx into the terminal and
promote vesicular fusion. Conversely, activation can cause membrane
depolarization that is sufficient to trigger adjacent VGCCs which indirectly
increases Ca2+ influx. Regardless of the mechanism, pre-synaptic NMDARs have
been shown to influence spontaneous and evoked glutamate release (Banerjee,
Larsen, Philpot, & Paulsen, 2016). Conversely, there is little evidence for presynaptic AMPARs, as their presynaptic expression appears to be brain region
dependent (Rossi, Maton, & Collin, 2008).
Estimates suggest that each action potential releases one quanta of
glutamate that amounts to about 4000 molecules. Other estimations establish a
range of 3,000-10,000 molecules of glutamate following each action potential
(Barbour & Hausser, 1997; Clements, 1996; Pendyam, Mohan, Kalivas, & Nair,
2009). Regardless, this is sufficient to increase extracellular glutamate
concentration from the nM to the low mM range (0.5-1.0 mM) but only in the
aspect of the synaptic cleft that is most proximal to the release sites. This results
in a microdomain of high glutamate concentration that approximates the affinity
of AMPARs for glutamate (Rusakov, 2001).
The distribution of glutamate receptors on the post-synaptic terminal is
highly organized reflecting, in part, relative affinities for glutamate. Efficient
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signaling between the pre and postsynaptic neuron is influenced by the spatial
distribution of low-affinity AMPAR which are expressed on the closest aspect of
the post-synaptic membrane relative to the release sites and high-affinity
NMDAR and mGluRs being expressed more laterally. The localization of
glutamate receptors is largely driven by a transcellular protein bridge created by
neurexins, neuroligins and matricellular proteins that link the pre-synaptic release
machinery (SNARE complex) to the post synaptic density (PSD) that anchors
AMPARs and NMDARs (Christopherson et al., 2005; Eroglu et al., 2009; Hata,
Davletov, Petrenko, Jahn, & Südhof, 1993; Kania & Klein, 2016; Kucukdereli et
al., 2011). The transcellular protein bridge is significant because it ensures the
intimate localization of glutamate release sites with the post-synaptic terminal,
which makes synaptic signaling highly efficient. This level of efficiency is
required, in part because an estimated 50-90% of synaptic glutamate molecules
exit the cleft within 10-70 ms (Savtchenko & Rusakov, 2004). Thus, the
concentration of glutamate falls rapidly across temporal and spatial dimensions.
Activation of low-affinity AMPARs is more sensitive to spatiotemporal regulation
than high-affinity glutamate receptors such that lateral trafficking of AMPARs
represents a key form of synaptic plasticity influencing sensitization (for review
see, Rusakov, Savtchenko, Zheng, & Henley, 2011). Indeed, when AMPARs are
experimentally immobilized, they rapidly desensitize in response to glutamate
application which greatly reduces post-synaptic currents (Heine et al., 2008). As
a result, AMPARs are ideal targets for signaling mechanisms to exert powerful
control over the strength of synaptic transmission.
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While synaptic AMPARs function to rapidly transmit glutamate signals, the
function of synaptic NMDARs and mGluRs tend to be slower and are meant to
augment the function of AMPARs. Importantly, NMDARs are under a unique form
of regulation relative to AMPARs. Instead of regulation linked to glutamate affinity
and diffusion, a major regulatory mechanism for NMDARs is the voltagedependent physical occlusion of their ion pore by a Mg2+ ion. In order for this
block to be lifted, sufficient membrane depolarization via AMPARs is required
(Traynelis et al., 2010). Once lifted, NMDARs can conduct Ca2+ ions which can
activate a variety of intracellular signaling cascades that activate kinases and
trigger the synthesis of new proteins. Synaptic mGluRs synergize these effects
by also contributing to the propagation of Ca2+-dependent effects. Broadly, the
impact of synaptic NMDARs and mGluRs tend to stabilize the synaptic structure
and boost AMPAR-mediated signaling in a phenomenon referred to as long-term
potentiation LTP (Bliss & Collingridge, 1993). Thus, post-synaptic AMPARs,
NMDARs, and mGluRs synergize to effectively encode pre-synaptic glutamate
signals.
While diffusion of glutamate from the synapse represents an important
phenomenon for the regulation of synaptic signaling, the last component of the
synapse, the astrocytic process, is involved in synaptic glutamate clearance. It
has been theorized that for every molecule of glutamate released, roughly 4000
molecules per quanta, there is an equal number of transporters ready to remove
glutamate from the cleft. Specifically, the excitatory amino acid transporter
(EAAT) GLT-1, the most abundant astrocytic glutamate transporter in the brain,
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assumes the role as the primary glutamate clearance mechanism (Lehre &
Danbolt, 1998). Intriguingly, recent findings have demonstrated that GLT-1 is a
highly mobile protein in astrocyte membranes which is functionally relevant to
controlling glutamate within the synapse. Under periods of low neuronal activity,
GLT-1 is anchored at the synapse waiting for glutamate to be released. As
glutamate concentrations climb, GLT-1 binds glutamate and rapidly diffuses out
of the synapse allowing for unbound transporters to rotate in. Interestingly, when
GLT-1 is experimentally immobilized, its ability to clear glutamate is not impaired
but post-synaptic currents are increased, suggesting that GLT-1 has a dual
function in not only transporting glutamate into the astrocyte, but also moving it
away from low affinity AMPARs and into the extrasynaptic compartment (MurphyRoyal et al., 2015). Thus GLT-1 is important for maintaining the sensitivity of
AMPARs within the synapse and controlling the diffusion of glutamate out of the
synapse. Thus, the function of the peri-synaptic astrocytic process demonstrates
how important astrocytes are in the regulation of synaptic glutamate signaling.
The basic elements of glutamate’s actions in the synaptic cleft involving
the activity-dependent release, diffusion across a synaptic cleft, and activation of
postsynaptic receptors resembles what has been in place throughout much of the
evolution of metazoan nervous systems. In other words, synaptic glutamate is
among the most ancient of signaling processes (Moroz, 2009, 2015; Moroz &
Kohn, 2016; J. F. Ryan & Chiodin, 2015; J. F. Ryan et al., 2013). However,
nervous systems have expanded upon this essential unit of the nervous system
by increasing the complexity of intercellular communication through establishing
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a network of glutamate receptors, transporters, and release mechanisms
distributed outside of the synapse on both neurons and astrocytes.
Glutamate Signaling in the Extrasynaptic Space
The opportunity to increase the complexity of signaling in the brain likely
required extrasynaptic signaling. Estimates suggest that the synaptic cleft
represents 2% or less of the total interstitial space (Rusakov, Harrison, &
Stewart, 1998). Evolution has equipped the remaining 98% of interstitial space
with glutamate receptors, transporters, and release mechanisms that are
expressed throughout the full extent of neuronal and astrocytic cellular
membranes, which provides the molecular basis for the diverse forms of
signaling. Importantly, the extrasynaptic compartment conveys unique forms of
information transfer relative to the synapse. As a result, synaptic and
extrasynaptic glutamate signaling occurring between neurons or between
neurons and astrocytes can be segregated into functionally distinct, specialized
signaling zones or microdomains (Dityatev, Seidenbecher, & Schachner, 2010;
Le Meur, Galante, Angulo, & Audinat, 2007; Malarkey & Parpura, 2008;
Moussawi, Riegel, Nair, & Kalivas, 2011; Papouin & Oliet, 2014; Wu, Grebenyuk,
McHugh, Rusakov, & Semyanov, 2012). Given the massive surface area of the
extrasynaptic compartment, it is physically created by the two most abundant
cells in the brain: astrocytes and neurons. Of particular interest to this work is the
contribution of astrocytes to the extrasynaptic space which includes monitoring
neuronal activity, integrating neuronal information, and transforming that
information into a functional output to influence the activity of entire neural
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networks. Astrocytes achieve this through the reception and release of a variety
of neuroactive substances such as glutamate and trophic factors (e.g., BDNF,
TGF-β) (Verkhratsky, Matteoli, Parpura, Mothet, & Zorec, 2016).
Regarding how astrocytes can monitor and integrate neuronal information,
glutamate that enters the extrasynaptic compartment can gain access to
receptors present on astrocytes which are largely thought to be mGluRs.
Notably, the expression of functional ionotropic receptors in astrocytes (primarily
NMDARs and AMPARs) varies greatly depending on brain region and
experimental conditions and will not be discussed here (Hoft, Griemsmann,
Seifert, & Steinhauser, 2014). The two most predominant mGluRs expressed by
astrocytes are mGluR5 and mGluR3 (Bradley & Challiss, 2012; Schools &
Kimelberg, 1999) which belong to group 1 and group 2 respectively. MGluR5
activation by glutamate triggers phospholipase C activity which produces inositol
triphosphate (IP3) and diacylglycerol (DAG) resulting in Ca2+ release from the
endoplasmic reticulum. Intriguingly, the Ca2+ response oscillates with mGluR5
activation, which is dependent on a PKC mediated negative feedback loop which
momentarily phosphorylates mGluR5 and decouples it from Gαq. Importantly,
increasing glutamate concentrations has no effect on the frequency or amplitude
of Ca2+ oscillations once the signaling loop has been initiated. In a sense, this
cascade is “all or none” and simply encodes the presence of sufficient activity
from adjacent neurons. The functional consequence of mGluR5 activation and
these Ca2+ oscillations is still under investigation, but one of the current theories
suggests that activation of mGluR5 enhances glutamate uptake into the astrocyte
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via increasing GLT-1 expression which facilitates clearance of extracellular
glutamate (Devaraju, Sun, Myers, Lauderdale, & Fiacco, 2013; Umpierre, West,
White, & Wilcox, 2019; Vermeiren et al., 2005).
MGluR3, while having a different G-protein coupling mechanism, has
some similarities in function with mGluR5 in astrocytes. Activation of mGluR3 has
been shown to produce enhancements in glutamate transporter expression
(Aronica et al., 2003), which suggests that the astrocytic mGluRs serve
redundant functions in receiving qualitative information about nearby neuronal
activity and consequently working to reduce the concentration of extracellular
glutamate. Thus, activation of either receptor can serve as a neuroprotective
mechanism against glutamate induced excitotoxicity. For example, mGluR3 has
been shown to increase the production and release of trophic factors such as
TGF-β and NGF which can act synergistically on adjacent neurons to promote
survival (Bruno et al., 1998; Ciccarelli et al., 1999). Additionally, mGluR5
facilitates neuroprotective effects via astrocytes in a model of ischemic stroke
(Cavallo et al., 2020) With both the actions of both mGluR3 and 5 in astrocytes
considered, the net effect of glutamate acting on these receptors appears to be
maintaining extracellular glutamate levels within a safe range while at the same
time providing neuroprotective factors.
An emerging principle of brain function is that astrocytes can actively
release glutamate to regulate neurons (Baker, Xi, Shen, Swanson, & Kalivas,
2002; Jourdain et al., 2007; Martin, Bajo-Graneras, Moratalla, Perea, & Araque,
2015). Notably, the actions of glutamate released by astrocytes can be
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functionally distinct from neuronally derived glutamate due to spatial and
temporal receptor activation parameters. In other words, astrocytes may target
glutamate release to a population of neuronal receptors that are distal from
synaptic release sites. These receptors are often embedded in large protein
complexes and have different functions relative to their synaptic counterparts.
For example, extrasynaptic NMDARs have been detected in highly-specialized
protein complexes that are often anchored near adjacent astrocyte processes
(Petralia et al., 2010; Sah, Hestrin, & Nicoll, 1989), and extrasynaptic NMDARs
can have effects on the neuron that are opposite to synaptic NMDAR activation
such as producing an attenuation rather than enhancement of excitatory output
(Papouin & Oliet, 2014). Thus, understanding the factors regulating astrocytic
release of glutamate will be essential to understanding how astrocytes can
impact neural circuits and consequently behavior.
The mechanisms of glutamate release from astrocytes fall into two major
groups: channel/transporter mediated and vesicular mediated (Malarkey &
Parpura, 2008). For example, the cystine-glutamate antiporter system xc- (Sxc)
which represents a non-vesicular release mechanism, has been shown to
release glutamate that can activate pre and post-synaptic glutamate receptors in
the striatum and hippocampus to regulate synaptic strength (Baker et al., 2002;
Lewerenz et al., 2013; Williams & Featherstone, 2014). Similarly, ultrastructural
electron microscopy studies provide evidence for vesicles containing glutamate
in hippocampal astrocytes proximal to pre-synaptic neuronal NMDARs which
when activated enhance synaptic glutamate release and strength (Bezzi et al.,
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2004; Jourdain et al., 2007; Xu et al., 2007). Furthermore, TREK-1 and Best1,
which are both glutamate-permeable channels, serve as fast/phasic and
slow/tonic mechanisms of glutamate release from astrocytes (Woo et al., 2012).
The significance of their differing transport velocities is revealed by their
respective activation of neuronal mGluRs and NMDARs which consequently tune
synaptic transmission. Given the variety of release mechanisms, a question that
needs to be resolved is under what specific circumstances do each of these
mechanisms become active and how might they be linked to or disrupted in
disease?
A common underlying factor that enhances glutamate release from
astrocytes is elevations in astrocytic intracellular Ca2+, which might explain how
some glutamate release mechanisms in astrocytes become active. As is the case
in neurons, Ca2+ is the key signal that mediates the fusion of vesicles with the
membrane via the SNARE complex, so it is likely that astrocytes have a similar
mechanism so long as the machinery is present. Indeed, electron microscopy
studies have shown the vesicular glutamate transporter VGLUT1/2 and SNARE
protein cellubrevin in hippocampal astrocytes (Bezzi et al., 2004). However, the
relevance of these findings to in vivo function remains a controversial topic. In
particular, the use of genetically modified mice designed to lack vesicular release
machinery in astrocytes in experiments seeking to investigate its role in
regulating neural networks in vivo revealed transgene expression in neurons
which quelled of the relevance of the findings (Bohmbach, Schwarz, Schoch, &
Henneberger, 2018; Fujita et al., 2014). However, even without vesicular release
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machinery, Ca2+ can also impact transporter-mediated glutamate release such as
through Best1 (Sun, Tsunenari, Yau, & Nathans, 2002). Likewise, volumeregulated anion channels (VRACs) are opened during astrocytic swelling which
can release excitatory amino acids such as glutamate (Kimelberg, Goderie,
Higman, Pang, & Waniewski, 1990). VRACs do appear to be somewhat sensitive
to Ca2+, as Ca2+-dependent astrocyte swelling stimulated their opening. While it
is unknown whether other transport mechanisms have a documented Ca2+
sensitivity, it is certainly possible that Ca2+ dependent kinases may regulate
transporter activity through phosphorylation. More work is needed to explore this
possibility.
Glutamate release from astrocytes can occur even in the absence of Ca2+
signaling. For example, the purinergic receptor P2X7 is a ligand-gated ion
channel activated by ATP that is capable of releasing glutamate and is not
negatively impacted by a lack of Ca2+ (Duan et al., 2003). Additionally, the
connexin 43 hemichannels, which are capable of transporting glutamate,
glutathione, ATP, as well as cations do not appear to be activated by Ca2+, rather
they serve an important role in balancing Ca2+, among other molecules, across
the cell membrane (Liang et al., 2020).
Considering the mechanisms of glutamate release from astrocytes and the
power that they have in regulating neurons, lingering questions arise regarding
how these components impact cognitive processing and behavior. An emerging
viewpoint of the field, and the one that will be established by the experiments in
the following chapters is that neurons and astrocytes work together to dictate
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how glutamate engages its receptors to regulate neural networks and cognition.
The overarching question that will be answered by these experiments is whether
astrocytes were involved in the expansion of cognitive abilities in vertebrates due
to their ability to process and disseminate information through glutamate.
Ultimately, do these cells contain the glutamatergic components that enhanced
our cognitive abilities that when disrupted make us vulnerable to cognitive
disorders?

26
CHAPTER II
THE ROLE OF SYSTEM XC- IN COGNITION AND THE REGULATION OF
NEURAL CIRCUITS

INTRODUCTION
Cognitive deficits contribute to the disease burden associated with
numerous disorders including mental health, cancer, diabetes, heart disease,
and obesity (Cannon et al., 2017; Harrison & Wefel, 2018; He, Ryder, Li, Liu, &
Zhu, 2018; Jones, Gray, & Hemsley, 1992; Lange, Seer, & Kopp, 2017; P. M.
Moran, Owen, Crookes, Al-Uzri, & Reveley, 2008; Rock, Roiser, Riedel, &
Blackwell, 2014; Y. Yang, Shields, Guo, & Liu, 2018). Mental health disorders in
particular such as depression and substance abuse register as leading causes of
disease burden in high-income countries (DiLuca & Olesen, 2014; Gustavsson et
al., 2011; Lassek, Weingarten, & Volknandt, 2015; Olesen & Leonardi, 2003;
WHO, 2008). Considering this, resolving cognitive dysfunction would greatly
reduce disease burden. While this renders the development of safe, effective
cognitive pharmacotherapies as a high priority, there has been insufficient
progress due to critical gaps in our understanding of the cellular and molecular
basis of cognition in the brain. An emerging viewpoint is that the molecular basis
of cognition in vertebrates likely arose from the evolutionary enhancement of
signaling complexity in the brain (Emes et al., 2008; Nithianantharajah et al.,
2013), which may support novel strategies to understand and treat cognitive
dysfunction.
The evolutionary expansion of glutamate neurotransmission contributed to
the signaling complexity needed for the progression of cognitive ability. For
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example, synaptic glutamate became an important form of intercellular signaling
early in the evolution of nervous systems and has become the most ubiquitous
neurotransmitter, as evidenced by its inclusion in nearly 95% of cortical synapses
(Kasthuri et al., 2015; Moroz et al., 2014; T. J. Ryan & Grant, 2009; Schousboe,
1981). Indeed, relatively recent adaptations such as the expression of novel,
functionally distinct NMDAR subunits contributed to enhanced signaling
complexity in synapses which expanded the amount of information that could be
encoded by glutamate (Teng et al., 2010). Beyond this, the human brain has
been further equipped with glutamate receptors and release mechanisms
(Lewerenz et al., 2013; Malarkey & Parpura, 2008), expressed by non-neuronal
cells and in non-synaptic domains (Chiu, DeSalle, Lam, Meisel, & Coruzzi, 1999;
Papouin et al., 2017; Tikhonov & Magazanik, 2009). A major question is whether
or not these non-synaptic, non-neuronal adaptations are relevant to the
expansion of signaling complexity within neural networks and were essential to
the enhanced cognitive ability of higher vertebrates.
The acquisition of novel genes encoding astrocytic glutamate-release
mechanisms that signal within non-synaptic domains may have been key in
expanding the processing power of neural circuits and consequently, cognitive
abilities. In support, a human cortical astrocyte contacts millions of synaptic units,
which is considerably more than neurons and allows them to communicate with
and regulate entire neural networks (DeFelipe, Alonso-Nanclares, & Arellano,
2002; Oberheim et al., 2009; Oberheim et al., 2006). Indeed, computational
models reveal that astrocyte-neuron signaling significantly improves the
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performance of neural networks, especially when the size of the network or the
complexity of the information is maximized (Alvarellos-Gonzalez et al., 2012;
Porto-Pazos et al., 2011). Additionally, biological studies demonstrate that
astrocytes exert complex regulation over neural networks, which can include the
gating of specific circuits or increased network synchronization (H. S. Lee et al.,
2014; Martin et al., 2015; Poskanzer & Yuste, 2016; Sardinha et al., 2017). While
there are a variety of mechanisms that release glutamate from astrocytes
(Malarkey & Parpura, 2008) there is a critical gap in our understanding of their
individual and collective roles in neural network regulation and cognition.
Consequently, there has only been a recent appreciation for the possibility that
astrocytes are active players in cognition which is striking considering the degree
of influence they exert over neural networks (Santello et al., 2019).
In the studies described in this chapter, we investigated the role of the
cystine-glutamate antiporter system xc- (Sxc) in the regulation of neural circuits
and cognition. Sxc releases intracellular glutamate in exchange for extracellular
cystine (Baker et al., 2002; Warr, Takahashi, & Attwell, 1999). It is a heterodimer
of the subunits xCT and 4F2hc, which are encoded by the genes Slc7a11 and
Slc3A2, respectively. Importantly, the xCT subunit serves as the catalytic subunit
whereas the 4F2hc guides and anchors it in the membrane (de la Ballina et al.,
2016; Sato, Tamba, Ishii, & Bannai, 1999; Shih & Murphy, 2001). Intriguingly, the
observed expression patterns of Slc7a11 establish Sxc as an evolutionarily-new
glutamate-release mechanism expressed by astrocytes (Lewerenz et al., 2013;
Ottestad-Hansen et al., 2018) and is present in brain regions involved in
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cognitive processing such as the hippocampus, amygdala, prefrontal cortex, and
nucleus accumbens (Baker, McFarland, Lake, Shen, Tang, et al., 2003; Lutgen
et al., 2014).
In the nucleus accumbens core (NAcc), Sxc activity is negatively impacted
by self-administration of drugs of abuse which has made it a focus for therapeutic
intervention in substance abuse patients (Kalivas, 2009). In support, Sxc activity
is reduced following self-administration of cocaine in rats resulting in reduced
extracellular glutamate in the NAcc. This reduction is thought to produce drug
seeking through a mGluR2 dependent mechanism whereby a reduction in its
activity produces a disinhibition of glutamate release from cortical afferents;
enhancing excitatory drive on NAcc efferents and consequently promoting drug
seeking (Baker et al., 2002). Intriguingly, restoring extracellular glutamate levels
using drugs that may target Sxc such as n-acetylcysteine reduces drug seeking
during drug primed reinstatement tests (Baker, McFarland, Lake, Shen, Tang, et
al., 2003). The use of n-acetylcysteine has also shown efficacy in clinical models
of cocaine addiction, where a four-day treatment regimen attenuated cocaine
craving following an I.V. infusion (Amen et al., 2011). Furthermore, nacetylcysteine has a similar efficacy in preclinical and clinical studies of heroin
(Zhou & Kalivas, 2008) and nicotine (Schmaal et al., 2011) addiction as well as
other compulsive disorders such as binge eating (Hurley et al., 2016) and
Prader-Willi syndrome (J. L. Miller & Angulo, 2014). These studies lend support
to Sxc having a significant impact on neuronal signaling and behavioral control
and is a promising therapeutic target.
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Given the novelty of Sxc expression in animal species, its ability to
regulate synaptic glutamate, and its potential to influence cognition, we sought to
further elucidate the biological significance of its expression in a mammalian
system. To do this, we developed a novel rat strain that lacks functional Sxc
(Figure 2-1B, MSxc rat). With this tool, we tested the hypothesis that global
removal of Sxc in a rat would sufficiently disrupt neural networks and cognition in
a manner that produces maladaptive behavioral phenotypes. Furthermore, the
MSxc rat will help resolve whether astrocyte to neuron signaling was a key event
in achieving the signaling complexity needed for executive function and cognition
in mammals.
MATERIALS AND METHODS
Chemicals: Unless noted, common chemicals and reagents were obtained from
Sigma Aldrich.
Animal care and usage: Male Sprague Dawley rats were used for these
experiments. Housing conditions and experimental protocols were approved by
Institutional Animal Care and Use Committees at the Medical College of
Wisconsin or Marquette University, and were carried out according to the US
National Institutes of Health guidelines.
SLAC Analysis: mRNA protein coding sequences from the SLC7A11 gene from
115 organisms were retrieved from Genbank (Benson, Karsch-Mizrachi, Lipman,
Ostell, & Sayers, 2009). Partial and isoform sequences were left out of this study.
Sequences were aligned by codon using MUSCLE (Edgar, 2004) in the MEGA6
software package(Tamura, Stecher, Peterson, Filipski, & Kumar, 2013) and
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manually reviewed for accuracy. The aligned sequences were run through
MEGA6 model selection software using a neighbor-joining tree and a maximumlikelihood statistical method. Gaps were treated by partial deletion and were not
used for computing tree branch lengths. The K2+G (gamma distributed) model
was utilized to construct a phylogenetic tree. Pairwise distances were estimated
with uniform rates and partial deletion of gaps. Bootstrap values were generated
from 100 replications. A cutoff tree was computed with a minimum bootstrap
value of 70. Sequence motifs for specific consensus phosphorylation sites were
searched within the alignment and conservational data was manually extracted
based on the existence or absence of the site. Determination of sites under
positive or negative selection was carried out using the Datamonkey web server
(Delport, Poon, Frost, & Kosakovsky Pond, 2010). SLAC, branch-based SLAC,
FEL, and an integrative selection analysis (Kosakovsky Pond & Frost, 2005)
were carried out using a neighbor joining tree at a 0.05 significance level.
Creation of GFAP:Lck-eGFP transgenic rats: The Sleeping Beauty (SB)
transposon transgenesis method (Geurts et al., 2010) was used to produce
transgenic rats on the Sprague Dawley (Crl:SD) background. Briefly, a GFAP
promoter-driven fusion between the plasma membrane targeting myristolation
domain of the mouse LCK protein fused to eGFP(Benediktsson, Schachtele,
Green, & Dailey, 2005) was synthesized (GeneArt) and cloned into a SB
transposon vector. The transposon plasmid was co-injected with a source of
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Figure 2-1: Quaternary and primary structure of Sxc and xCT. A, The quaternary
structure of Sxc is comprised of the heavy chain subunit (4F2hc a.k.a. CD98) and the
transporter subunit xCT which contains 12 transmembrane domains. B, The primary
structure of the protein coding sequence of xCT. Area highlighted in red defines the target for
the mutation that created the xCT mutant (MSxc) rat which corresponds to the third
transmembrane domain seen in A.

SB100X transposase mRNA into the pronucleus of fertilized Crl:SD embryos. A
breeding colony was established harboring a single copy of the transgene
inserted on rat chromosome 13 enabling robust eGFP expression. To confirm
expression in situ, a rat was deeply anesthetized and transcardially perfused with
4% paraformaldehyde. The brain was extracted and sliced at 100 µm and GFP
signal was visualized using standard fluorescence microscopy.
Creation of MSxc rats: Zinc-finger nucleases (ZFNs) were designed targeting
the second exon sequence (TGCTAGCTTTTGTTCgagtcTGGGTGGAACTGC
TG) to produce small deletions of a limited number of base pairs in the Slc7a11
gene, where capital letters represent binding sites for the individual ZFN
monomers, on opposite strands (Figure 2-1). ZFNs were injected into the
pronucleus of Sprague Dawley (Crl:SD) rat embryos by pronuclear microinjection
of in vitro-transcribed encoding messenger RNAs and the resulting offspring
were screened for mutations using a Cel-1 assay and validated by Sanger
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sequencing as previously described(Geurts et al., 2010) and resulting in singlestep, whole-animal disruption of Slc7a11 (MSxc rats). Deletion of 39 consecutive
base pairs (GAGGTCTTTGGTCCCTTGCTAGCTTTTGTTCGAGTCTGG) of
exon 2 was confirmed by Sanger sequencing.
Tissue Dissociation for FACS: NAc tissue was dissected from male GFAP-lckeGFP or WT Sprague Dawley rats and placed into ice-cold Hanks´ Balanced Salt
Solution without Ca2+ or Mg2+. Tissue was mechanically and enzymatically
dissociated to obtain single-cell suspension using Neural Tissue Dissociation Kit
- P (Miltenyi Biotec). 1% BSA, 1mM EDTA and 12.5 U/ml DNase I were added to
reduce cell clustering. Cells were incubated with 3 µM Calcein Violet 450 AM
Viability Dye (eBioscience) on ice for 10 minutes to stain live cells. An aliquot
from each cell suspension was used to determine relative gene expression in
sorted and unsorted (total) cells.
Flow Cytometry: FACS analyses were performed using FACSDiva software
6.1.3 (BD Biosciences). Control samples (tissue obtained from rats lacking the
GFAP:Lck-eGFP transgene) were analyzed first to identify the range of
endogenous or background fluorescence intensity. In addition, the gating
parameters of the flow cytometer were set to isolate live, eGFP+ cells from
cellular debris, and cell doublets. Note, the eGFP- samples contain all tissue
excluded from the eGFP+ sample and would be expected to include eGFP- cells,
cell doublets, fragmented cells, and potentially eGFP+ cells that were not
excluded due to the use of strict gating parameters or incomplete cellular
disassociation.
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RNA Extraction and Amplification of FACS samples: Total RNA from sorted
cells was isolated using PicoPure RNA Isolation Kit (Thermo Fisher Scientific).
On column DNase treatment was applied to all samples with the RNase-Free
DNase Set (Qiagen). RNA quantity and quality were assessed on an Agilent
2100 Bioanalyzer using Agilent RNA 6000 Pico Chips. Only samples with RNA
quality of RIN > 7.0 were used. Resulting RNA was amplified and reverse
transcribed using the cDNA synthesis from cell lysates kit (Lucigen).
RT-PCR/qPCR: Total RNA was extracted from NAcc tissue samples using Trizol
reagent and was subsequently treated with DNAse (Life Technologies) to remove
genomic DNA contamination. RNA purity and quantity were assessed using a
Nano Vue Plus spectrophotometer (GE Life Sciences). RNA (1 g) from each
sample was reverse transcribed for PCR (Promega). PCR was conducted using
GoTaq DNA polymerase (Promega). For analysis of FACS samples, qPCR was
conducted using SYBR green chemistry (Quantabio) in a 48-well StepOne realtime PCR system (Applied Biosystems). Primer sequences were as follows:
Slc7a11 (xCT) forward- 5’ AGG GCA TAC TCC AGA ACA CG 3’; Slc7a11
reverse- 5’ TTT AGT CCC ATC AGG TCG TTG 3’; GAPDH forward- 5’ CTC CCA
TTC TTC CAC CTT TGA 3’; GAPDH reverse- 5’ ATG TAG GCC ATG AGG TCC
AC 3’. GFAP forward - 5’ GCA GGT GAG GAA GAA ATG GA 3’; GFAP reverse 5’ TAC GAT GTC CTG GGA AAA GG 3’; NeuN forward - 5’ ATC ATA CCA TCG
GCC CCA CA 3’; NeuN reverse - 5’ GTG AAG CGG CTG TAC CCT CC 3’.
Western Blotting: NAcc tissue samples obtained from adult WT and MSxc rats
(i.e., > 90 days old) underwent mechanical homogenization in a sucrose-based
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buffer (300 mM sucrose, 10 mM Tris-HCl, pH 7.4) containing protease and
phosphatase inhibitors (Thermo Fisher Scientific). Protein concentration for each
whole cell lysate sample was determined via the bicinchoninic acid assay (BCA).
Protein (10 g) was resolved in a 7.5% polyacrylamide gel and wet transferred to
Immobilon PVDF membranes (EMD Millipore). Membranes were immersed for
one hour in blocking buffer (LiCor) prior to overnight application at +4°C with a
primary antibody: rabbit anti-mGluR2/3 (Upstate, 1:3000) rabbit anti-EAAT2
(1:3000) rabbit anti-pT840 GluA1 (Abcam, 1:3,333) rabbit anti-pS845 (Abcam,
1:1000) mouse anti-GluA1 (EMD Millipore, 1:1000) chicken anti-GAPDH (EMD
Millipore, 1:10,000) rabbit anti-xCT (generated by Dr. Rothstein, 1:500).
Secondary antibodies (LiCOR) goat anti-rabbit IR 680 DYE (1:15000) donkey
anti-mouse IR 800 DYE (1:20,000) and donkey anti-chicken IR 800 DYE
(1:20,000) were applied for 1 hour at room temperature prior to imaging
(Odyssey Fc Imaging System, Licor). Band intensity was quantified using LiCOR
Image Studio software and the resulting data are presented as the target protein
band intensity divided by the reference protein band intensity.
Cell Culture: Astrocyte cultures were generated from postnatal day-3 rat pups.
The striatum was dissected and dissociated using 0.25% trypsin EDTA (Gibco)
and cultured in 75 cm2 flasks in a humidified incubator at 37°C under 95% O2 5%
CO2 in Eagles minimum essential medium (Gibco) supplemented with 5% fetal
bovine serum/5% horse serum (Atlanta Biologicals), Glutamax (Gibco), and
antibiotics/antimycotics (Gibco). To remove debris and non-astrocytic glia, flasks
were agitated, and the resulting mono-cell layer was resuspended with 0.25%
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trypsin EDTA. Cells were counted by hand via a cytometer and seeded in 24-well
plates coated with poly-D-lysine and laminin at a density of 200,000 cells per
well.
14C-L-Cystine

and 3H-D-Aspartate uptake assays: These assays were used to

determine Sxc and EAAT function, respectively. NAcc tissue punches or
astrocyte cultures obtained from adult WT and MSxc rat were incubated for 20
minutes in artificial cerebral spinal fluid (aCSF) and maintained at 37oC under
95% O2 5% CO2 conditions. For D-aspartate uptake, NAcc tissue or cultured
cells were then incubated for 30 minutes in 1 M 3H-D-aspartate dissolved in
aCSF. Likewise, for 14C-L-Cystine (1 M), tissue was incubated for 30 minutes.
For each study, tissue punches or cells were then dissolved in 300 l of 1%
sodium dodecyl sulfate (SDS). A 200 l aliquot was used for scintillation counting
(Beckman 6500) and a 25 l aliquot was used for protein determination using the
BCA assay.
Cystine-evoked glutamate release assay: In order to measure Sxc function,
striatal astrocytes (DIV14) were incubated for 30 minutes at 37oC in Na+-free
buffer containing the following: 116 mM choline chloride, 13.4 mM MgSO4, 1.68
mM KH2PO4, 2.34 mM CaCl2, 5.49 mM dextrose, 11.9 mM HEPES, 0.2% choline
bicarbonate, titrated to pH: 7.4 with CeOH. This buffer was used to prevent Na+dependent uptake of glutamate. Increasing concentrations of L-cystine 0, 12.5,
25, 50, 100, 200 M were applied to drive cystine-glutamate exchange by Sxc.
Media samples (100 l) were collected for subsequent glutamate analysis using
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high performance liquid chromatography (HPLC). Cells were then dissolved in
0.5% SDS and total protein for each well was quantified using the BCA method.
Glutamate HPLC: The concentration of glutamate was quantified by comparing
peak areas from samples and external standards using HPLC coupled to
fluorescence detection. A 10 l sample underwent pre-column derivatization with
orthophthaladldehdye (OPA) in the presence of 2-mercaptoethanol using a
Shimadzu LC10AD VP autosampler. Chromatographic separation was achieved
using a Kinetex XB C-18 (50 x 4.6 mm, 2.6 m; Phenomenex) and a mobile
phase consisting of 100 mM Na2HPO4, 0.1 mM ethylenediaminetetraacetic acid
(EDTA), 10% acetonitrile at a pH of 6.04. Glutamate was detected using a
Shimadzu 10RF-AXL fluorescence detector with an excitation and emission
wavelength of 320 and 400 nm, respectively. Glutamate content for each sample
was normalized to total protein in the respective well and depicted as a net
change from baseline. The data was fit using the Michaelis-Menten equation to
determine Km and Vmax.
Rhodamine tracer injection: In order to label NAcc efferent pathways, adult rats
were anesthetized with ketamine/xylazine and underwent stereotaxic surgery.
Guide cannula (Plastics One) were implanted into the brain targeting the SN (0°,
-5.0 mm anterior-posterior, +2.1 mm medial-lateral, -6.1 mm dorsal-ventral) or VP
(0°, -0.6 mm anterior-posterior, +2.8 mm medial-lateral, -6.3 mm dorsal-ventral).
Micro-injectors (Plastics One) were inserted into guide cannula and extended at
least +2.0 mm from the distal aspect of the guide cannula for placement into the
target structure. Rhodamine fluorescent latex microspheres (300 nl; Lumafluor)
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were injected into the target region. Animals recovered for at least 2 weeks prior
to use in experiments.
Brain slice preparation and electrophysiology: Adult rats were anesthetized
by isoflurane inhalation and perfused through the aorta with a cold sucrosebased solution (4–6 °C) containing (in mM): 78 NaCl, 68 sucrose, 26 NaHCO3,
2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 2 MgCl2 and 25 glucose. The brain was
trimmed and embedded in low-melting-point agarose, and coronal striatal slices
(200-250 m thick) were cut in the sucrose-based solution (4-6 °C) using a
vibrating slicer (Leica VT1200s). Slices were initially incubated in the above
sucrose-based solution at room temperature (30-40 min) and were then
transferred and stabilized (30 min) in an aCSF solution containing (in mM): 119
NaCl, 2.5 KCl, 2.5 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, and 10 glucose.
All solutions were saturated with 95% O2 and 5% CO2. Whole-cell recordings
were made using patch clamp amplifiers (Multiclamp 700B) under infrareddifferential interference contrast optics (Nikon Eclipse FN1 and Olympus
BX51WI) and a 40x water immersion lens. Data acquisition and analysis were
performed using DigiData 1440A and 1550B digitizers and analysis software
pClamp 10 (Molecular Devices). Signals were filtered at 2 kHz and sampled at 10
kHz. Whole-cell patch-clamp recordings were made from rhodamine beadlabelled medium spiny neurons (MSNs) in NAcc slices. MSNs were also
identified visually by their medium-sized, spindle-like cell bodies, large initial axon
segment, and electrophysiological characteristics as described in our previous
studies (Liu et al., 2013; Wang et al., 2010). Glass pipettes (4-6 MΩ) were filled
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with one of the following internal solution (in mM): 130 K-gluconate, 10 KCl, 10
HEPES, 1 EGTA-Na, 2 Mg-ATP, 0.3 Na-GTP, and 10 Na2-phosphocreatine at pH
7.2 (with KOH). Neurons were voltage-clamped at −70 mV. A bipolar tungstenstimulating electrode was placed at the prelimbic cortex–NAcc border to
stimulate afferent cortical fibers. The GABAA receptor blocker picrotoxin (100 μM)
was freshly prepared and dissolved in aCSF using sonication (∼10 min). For the
recordings of paired-pulse ratio, two consecutive stimuli with 20-400 ms intervals
were applied. For the recordings of miniature excitatory postsynaptic currents
(mEPSCs), the Na+ channel blocker tetrodotoxin (TTX, 0.5 M, Tocris) was
added to the aCSF solution to block action potentials.
Physiology Telemetry: Adult rats were implanted intraperitoneally with
telemetry probes (Mini-Mitter Inc.) to remotely record core body temperature and
locomotor activity while in their home cage. Temperature and activity data were
collected every 5 minutes and averaged in 1-hour bins.
Open Field: Adult rats were placed into an open-field chamber (150 x 100 x 40
cm) and oriented toward a wall to begin the 15-minute session. The amount of
time animals spent in the center zone (defined as 15 cm from each wall) and the
total distance travelled was recorded using video-tracking software (EthoVision).
Novel Object Recognition: During the first two days, rats underwent five-minute
habituation sessions, which involved placing the rats in a 50x25cm bedding-free
chamber outfitted with a camera. On the third day, rats were placed into the
maze for five minutes to become familiarized with two identical objects that were
placed in adjacent corners of the chamber. One hour later, rats were placed into
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the maze for five minutes, which had one “familiar” object and one novel object.
The time spent interacting (looking/sniffing/climbing) with each object was
recorded during each session on the third day. The placement and identity of
each object were randomized to control for object and spatial preference.
Pavlovian Conditioned Approach (PCA) and Omission testing: Adult WT and
MSxc rats were subjected to an PCA (also known as autoshaping) paradigm
using touch screen operant chambers (Campden Instruments) (Horner et al.,
2013). Briefly, rats were food deprived to approximately 90% of their ad libitum
mass and handled daily for a week prior to training. On the first day of training,
animals were habituated to the chambers for 20 minutes with 20 chocolate
flavored sucrose pellets placed in the reward delivery tray. If the subject
consumed all of the pellets, they progressed to the second phase of habituation
which entailed a 30-minute training session whereby following a variable intertrial
interval (0-30s) a reward is delivered in the tray concurrent with a tray light and a
1 second 3 KHz sound. If 40 trials are completed, i.e. 40 rewards consumed, the
subject progressed to PCA training. PCA training entailed five days of 20
presentations of CS+ and CS- for a total of 40 total trials. Cues were presented
when both a variable intertrial interval had passed and the infrared beam in the
back of the chamber was broken. Cues were presented for 10s and if CS+ was
presented, cessation was immediately followed by reward delivery with
concurrent tray light and a 1 second 3 KHz sound. Omission testing was the
same, however if the rat approached CS+ when it was presented, a reward
would not be delivered.
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Fear Blocking and Extinction: Adult rats were trained using a within-subjects
Kamin fear blocking design (Furlong, Cole, Hamlin, & McNally, 2010). This
design consisted of four stages across 5 consecutive days: stimulus preexposure (Stage 0), fear conditioning (Stage 1; 2 days), blocking (Stage 2), and
testing (Stage 3). Two 30-second auditory cues and two 30-second visual cues
were used in this experiment: CSA, constant cue-light illumination; CSB, 72-dB
white noise; CSC, 1-Hz flashing cue-light; CSD, 72-dB 6-kHz tone. Chambers
used for training (Stages 0-2) and testing (Stage 3) differed in texture and odor.
In each session, rats were acclimated to the chamber for 120 sec before stimulus
presentation (Baseline period). The inter-trial interval was 60 sec in Stages 0 and
3 and 240 ± 20 sec in Stages 1 and 2. During Stage 0, rats were presented with
each of the four CSs twice in a pseudorandom order. During Stage 1, rats
received four presentations of Cue-A co-terminating with a 1-sec foot-shock
unconditional stimulus (UCS; 0.5 mA) on each of two days. During Stage 2, rats
received alternating presentations (2 each) of compound cues AB and CD, coterminating with the UCS. During Stage 3, rats were briefly returned to the
training chamber for 10 minutes in the absence of stimuli to assess contextual
fear. Two hours later, rats were tested in a novel chamber for fear to Cue-B and
Cue-D in the absence of foot shock (Stage 3) with each stimulus being presented
four times. At least seven days following the completion of the fear blocking
experiment, all rats received an extinction session in the testing chamber. This
session consisted of 40 unreinforced presentations of Cue-A (30 sec) with an
inter-trial interval of 60s. The following day, rats were tested for their extinction
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memory; they were again placed in the extinction chamber and received 8
unreinforced CSAs. Freezing was defined as the cessation of all movement
except that needed for respiration and was used as the measure of conditional
fear during all training and testing sessions(Fanselow & Bolles, 1979). Freezing
was scored automatically using FreezeScan 2.0 (CleverSys).
Attentional Set Shifting: Adult rats were food-restricted to 90% of their ad
libitum body mass for one week. Next, rats were habituated to a four-arm cross
maze (60 x 20 x 12 cm). For each of the three test sessions, rats were run in
blocks of 12 trials. For each trial, only three of the four arms were made
accessible by blocking the fourth arm, thereby creating a T shaped-maze. In this
configuration, one arm was used as a starting chamber; the arms to the left and
right of the starting location were used as choice arms. Each of the choice arms
had a small divider at the distal end to prevent subjects from visually identifying
which choice arm contained a sucrose pellet. On each of the three test sessions,
a visual cue (a laminated paper with black and white stripes) was placed in one
of the choice arms. Following the completion of 12 trials, the configuration of the
maze rotated such that the arms representing the starting and choice arms could
be adjusted, thereby minimizing the utility of spatial cues outside the maze.
Testing continued until the subjects successfully identified the baited arm in ten
consecutive sessions. On the first daily test session, rats needed to acquire a
simple visual discrimination to learn that the placement of the sucrose pellet was
indicated by the placement of the visual cue. On the second daily test session,
rats were required to utilize an extradimensional shift since the location of the
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sucrose pellet was indicated by a directional cue (e.g., always turn right or
always turn left) rather than a visual cue (which now indicated the location of the
sucrose pellet at chance levels). On the third day, rats were required to display
reversal learning since the solution involved a directional cue that was opposite
to that of day 2. Perseverative errors were calculated on days 2 and 3 and
represented errors due to rats’ applying the prior day’s strategy. Regressive
errors represented mistakes occurring after identification of the trial strategy (i.e.,
at least 75% correct within a block of 8 trials) but prior to achieving the trial
criterion (10 consecutive test trials).
Cocaine Self-Administration and Reinstatement: Adult rats were trained to
self-administer cocaine (0.5 mg/kg/inf, IV; 2 hr/day) or saline under a fixed-ratio
one schedule of reinforcement for 12 daily sessions (Madayag et al., 2010). Rats
then underwent a seven-day abstinence period, followed by extinction training
sessions, which were identical to the self-administration sessions except lever
presses resulted in saline infusions. Once rats met the extinction criterion of
fewer than 15 presses/day, reinstatement testing was conducted. Reinstatement
testing involved pretreatment with a low dose of cocaine (3 mg/kg, IP) ten
minutes prior to testing and recording lever pressing for 2 hours.
Statistical Analysis: Investigators were blinded to genotype for all behavioral
procedures. All data are presented as means + standard error of the mean.
Analyses of data sets comprised of only 2 groups were analyzed using two-tailed
Student’s t-test or the Kolmogorov-Smirnov test (K-S test) for nonparametric
analyses. Analyses of data sets comprised of three or more groups were
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analyzed using analysis of variance with Tukey post hoc test. To calculate PCA
scores during PCA training the following equation was used:

Analysis
Response Bias (C)
Probability Difference (F)
Latency Score (I)

Variable
CS+ Approach During CS+ (A)
Tray Entries During CS+ (B)
CS+ Approach Trials (D)
Tray Entry Trials (E)
Averaged Tray Entry Latency (G)
Averaged CS+ Approach Latency (H)

Equation
C = (A-B)-(A+B)
F = (D/20)-(E/20)
I = (G-H)/10
PCA Score = (C+F+I) / 3

The frequency and amplitude of mEPSCs were calculated for 3-5 min of
recordings. The analysis of mEPSCs was performed with cumulative probability
plots (Van der Kloot, 1991). The paired-pulse ratio (PPR) was calculated by
dividing the mean amplitude of the second EPSCs by that of the first EPSCs.
Results were deemed significant at p<0.05.
RESULTS
Intriguingly, the xCT subunit of Sxc is a relatively recent adaptation for
animal species (Lewerenz et al., 2013). Hence, analyzing the degree of
spontaneous mutations within the xCT sequence over the course of the evolution
of vertebrate species we could infer its functional importance to these organisms.
To determine this, a phylogenetic tree was constructed to help infer ancestral
divergence points based on the conservation of the sequence. The tree reveals a
pattern of divergence consistent with canonical vertebrate species trees whereby
the traditional classes (e.g. birds, reptiles, and mammals) form separate clades
(Figure 2-2A). Intriguingly, primates form their own clade which is suggestive of
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significant changes to the sequence giving rise to a unique xCT sequence
relative to other mammals.
One possibility is that the speciation event giving rise to primate xCT was
driven by the acquisition of novel kinase regulatory sites which could change its
function. Thus, the sequence was scanned for consensus phosphorylation sites
which revealed three candidate regions (Figure 2-2B). First, we detected serine
residue 26 (S26, CaMKII/MSK1 site) and found it to be present in 100% of the
primates analyzed but only in 45% of non-primate mammals. Next, S481
(CaMKII/MSK1 site) is only present in 79% non-primate mammals and 100% of
primates. Last, S185 (GSK3-β site) was present in 92% of vertebrate species.
This suggests that novel regulatory sites on the xCT sequence were acquired
during vertebrate evolution and may have given rise to speciation events or
provided an adaptive advantage to the species that acquired them. In the case of
humans and other animals, this could include more complex signaling leading to
more complex cognition or behavior.
Considering the acquisition of these regulatory sites, we next asked
whether there was evidence of the xCT sequence evolving under the influence of
positive or negative selective pressure. Positive selective pressure favors rapid
genetic changes that provide an adaptive advantage whereas negative selective
pressure works to resist sequence changes by purifying changes from a
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Figure 2-2: Phylogenetic analysis of vertebrate xCT. A, Phylogenetic tree illustrating the
xCT protein coding sequence relationship across 115 vertebrate species. Major ancestral
divergence points are evidenced by branch points (all greater than 70 bootstrap). B, The
percent of species within vertebrate classes that express designated xCT residues targeted by
their respective kinase; in order from left to right S26, S481, S185. C, Data depicts the degree
of non-synonymous (dNS) to synonymous mutations (dS; dN-dS) across the xCT sequence.
CaMKII, Ca2+/calmodulin-dependent protein kinase II; MSK1, mitogen and stress activated
kinase 1; GSK3-β, glycogen synthase kinase-3 beta.

population through a reduction in fitness i.e. acquisition of maladaptive traits (Eric
J. Vallender & Lahn, 2004). We hypothesized that the regulatory sites may have
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given the species that acquired them an adaptive advantage i.e. were positively
selected for. To test, a single-likelihood ancestor count (SLAC) analysis was
used to ascertain the degree of selective pressures driving these sequence
changes across vertebrate evolution (Kosakovsky Pond & Frost, 2005). This
analysis revealed that 395/564 (70%) of codons analyzed displayed a
significantly higher degree of nucleotide mutations that did not alter the amino
acid sequence (degree of synonymous mutations; dS) than mutations that did
alter the amino acid sequence (degree of non-synonymous mutations; dNS;
p<0.05; Figure 2-2C). There was no evidence for positive selective pressure in
the xCT sequence (0/564, p>0.05). The regulatory sites S185 and S481 were
under significant negative selective pressure (p<0.05) whereas S26 trended
toward negative selective pressure (p=0.08). These findings suggest that S26,
S185, and S481 did not provide an adaptive advantage to species that gained
them, rather their acquisition was rapidly stabilized and resisted further change.
Thus, xCT largely evolved under negative selection whereby changes to the
sequence would likely produce an organism with maladaptive traits. Collectively,
these data suggest that the phylogenetic signature of xCT indicates it was an
essential protein to vertebrate species.
Having established the phylogenetic importance of xCT to vertebrates, we
next sought to further strengthen our understanding of the cellular expression
profile of xCT. Models of glutamate signaling depict Sxc as an astrocytic
mechanism, but the in vivo support for this is limited (Ottestad-Hansen et al.,
2018). The GFAP:Lck-eGFP rat was developed to assist in isolating fluorescently
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Figure 2-3. xCT is expressed by GFAP positive cells in the NAcc.
A, Fluorescence photomicrograph of GFP expression in the rat brain. B, The transgene
used to fluorescently label-astrocytes in GFAP:Lck-eGFP rats. C, Levels of mRNA for the
neuronal control gene NeuN, the astrocytic control gene GFAP, and xCT in FACS-sorted
GFP+ and GFP- cells. *p<0.05, t-test. Special thanks to Dr. Alex Savtchouk for A.

labeled astrocytes from adult NAcc tissue via FACS in order to quantify xCT
expression in these cells (Figure 2-3B). The NAcc was chosen for our molecular
and cellular experiments since this subcortical structure integrates inputs from
throughout the brain and is consequently an essential nucleus for cognitive
processing (Floresco, Ghods-Sharifi, Vexelman, & Magyar, 2006; Svensson &
Ahlenius, 1983). Furthermore, glutamate signaling in this structure relies on Sxc
activity (Baker, McFarland, Lake, Shen, Toda, et al., 2003; Baker et al., 2002; M.
M. Moran, McFarland, Melendez, Kalivas, & Seamans, 2005). Gross
fluorescence microscopy demonstrates eGFP expression throughout the brain
(Figure 2-3A). QPCR revealed a lack of NeuN expression in GFP+ cells.
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Additionally, GFAP and xCT expression was significantly higher in GFP+ cells
relative to GFP- (Figure 2-3C; n=4/genotype: GFAP, t6=5.79, p<0.05; xCT,
t6=4.01, p<0.05). These data demonstrate that GFAP positive cells, astrocytes,
are the predominant cell type in the NAcc that expresses xCT.
Given the phylogenetic significance and the expression of xCT in
astrocytes, we next sought to determine the physiological and behavioral impact
of mutating xCT in a mammalian system. We hypothesized that this would
produce an animal with maladaptive traits. The MSxc rat was developed using
Zinc-finger nuclease technology which yielded rats that lacked xCT protein and
mRNA (Figure 2-4A-B). Next, an in vitro cystine-evoked glutamate release assay
was conducted to test if Sxc was functional. This revealed that cystine uptake
significantly increased extracellular glutamate in WT but not MSxc astrocytes
(Figure 2-4C; cystine, F5,79=1.736, p>0.05; genotype, F1,79 =47.963, p<0.05;
genotype x cystine, F5,79=2.67, p<0.05). Genotypic effects were present within
25, 50, 100, and 200 µM cystine (Tukey, p<0.05). Additionally, ex-vivo slices of
the NAcc from WT and MSxc rats were incubated in

14C-L-cystine

in the

presence or absence of the Sxc inhibitor sulfasalazine (SSZ) to determine if Sxcdependent cystine uptake was ablated. We report effects of genotype, SSZ, and
an interaction between these variables (Figure 2-4D; n=10-12 per
genotype/treatment; genotype, F1,42=54.392, p<0.05; SSZ, F1,42=53.221, p<0.05;
genotype x SSZ, F1,42=49.953, p<0.05). There was a significant effect of
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Figure 2-4: Validation of a Sxc-deficient rat model. A-B, xCT protein and mRNA
expression, respectively, in NAcc tissue samples obtained from WT and MSxc rats. C,
Cystine-evoked glutamate release was in cultured striatal astrocytes generated from PD3 WT
and MSxc tissue. D, Radiolabeled cystine uptake in NAcc ex-vivo slices from WT and MSxc
rats in the presence or absence of the xCT inhibitor sulfasalazine (SSZ). Two-way ANOVA,
Tukey test; C, * effect of genotype within given cystine, p<0.05; D, * effect of treatment within
genotype; + effect of genotype within treatment, p<0.05. Special thanks to Dr. Jeffrey
Rothstein for the xCT antibody used in A.

genotype within vehicle and an effect of treatment within WT (Tukey, p<0.05).
These data demonstrate that Sxc is functionally knocked out in MSxc rats.
To investigate the physiological and behavioral impact of loss of Sxc
function we first utilized paradigms that would test for genotypic differences in
physiological telemetry, development, exploratory behavior, and simple
associative learning which would indicate the presence of maladaptive traits. We
report a lack of a genotypic effect on postnatal growth rate (Figure 2-5A; n=2528/genotype; effect of genotype F1,51=0.33, p>0.05; week: F4,204=22.18, p<0.001;
genotype x time: F4,204=4.20, p<0.001; p> 0.05 when comparing genotype at
each week), diurnal core body temperature (Figure 2-5B; n=7-8/genotype;
genotype x time F120,1560=0.952, p>0.05; genotype F1,13=0.113, p>0.05; time
F120,1560=51.133, p<0.001), and home cage locomotor activity (Figure 2-5C;
n=12/genotype; genotype x day F7,91=0.458, p>0.05; genotype F1,13=0.331,
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Figure 2-5. Loss of Sxc does not produce widespread impairments in physiology or
behavior. A, MSxc rats did not display developmental deficits in the form of post-weaning
size or growth rates to adulthood. B, Central regulation of metabolism as reflected by
absolute or diurnal changes to core body temperature was unaltered in MSxc rats. C-D,
MSxc rats display normal levels of activity in familiar and novel environments. C, Telemetry
measures of general activity in the home-cage over a five-day period was not altered by
genotype. D, Activity levels and time spent in the center zone of a novel environment were
also similar between WT and MSxc rats. E, Simple recognition memory as assessed by
comparing time spent with a novel object did not differ between WT and MSxc rats. F,
Evidence that the capacity to form simple associations was unaltered in MSxc rats also
involved a lack of a genotypic effect on the number of trials needed to acquire a food or
cocaine-reinforced operant task. Special thanks to Dr. SuJean Choi’s Lab for B-C.

p>0.05; day F7,91=2.759, p<0.05). Additionally, there were no genotypic effects
on total distance or time spent in the center of an open field arena (Figure 2-5D;
n=12/genotype; total distance t22=1.60, p>0.05; center time t22=0.306, p>0.05) or
novel object recognition (Figure 2-5E; n=9/genotype; t16=0.216, p>.05).
Furthermore, MSxc rats did not differ from WT in trials needed to reach
completion criterion when tested in associative operant tasks reinforced with
sucrose (Figure 2-5F; n=19-31/genotype; t48=0.84, p>.05) or cocaine
(n=13/genotype; t24=0.903, p>.05). These data demonstrate that MSxc rats do

52
not appear to display maladaptive traits in physiology, basic memory tasks, and
simple associative learning.
To investigate whether maladaptive disruptions in cognition were present
in the MSxc rat, we first employed a Pavlovian-conditioned approach (PCA)
paradigm (Figure 2-6). PCA, also referred to as autoshaping, has been used to
model the process by which discrete stimuli are learned to be predictive of a
desired outcome, acquire motivational properties, and subsequently influence
behavior (Robinson, Yager, Cogan, & Saunders, 2014). The rationale for this
approach is that PCA allows us to assess the degree of “top-down” versus
“bottom-up” regulation of behavior i.e. behavior guided by a calculation of
discriminating relevant stimuli in accordance with previously acquired knowledge
about the probability of an outcome versus sensory input readily impacting
behavioral output, respectively (E. K. Miller & Cohen, 2001; Sarter, Givens, &
Bruno, 2001). In PCA procedures, CS+ (reward-predictive conditioned stimulus)
approach is viewed as a “bottom-up” driven behavior due to the incentive and
motivational value placed on CS+ by the subject, even though this behavior is not
required for reward delivery (Sarter & Phillips, 2018).
To ascertain the ability for the subjects to learn that the presentation of
CS+ is predictive of a reward delivery, tray entries, CS approaches and the
latency to enter were analyzed. A two-way repeated measure ANOVA was used
to determine genotypic differences, differences across the training session, and
any interaction between these variables on a within-subject basis. Regarding
CS+ tray entries (Figure 2-7A; n=9,10/genotype) we report a main effect of
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Figure 2-6. Pavlovian conditioned approach experimental design. A, Top- down view of
the Campden touch screen behavioral chamber. B, Front-view of the behavioral chamber
with two rectangular screens spanning the floor to ceiling flanking the reward tray. The
conditioned stimulus (CS) is a large visual X on the screen C, Flowchart for the training
paradigm. Approach toward CS+ is not required for reward delivery.

session (F4,68=34.227, p<0.05) with no effect of genotype (F1,68=1.108, p>0.05)
nor an interaction between these variables (F4,68=1.492, p>0.05). Notably, there
was an increase in tray entries by sessions 2-5 relative to session 1 (Tukey,
p<0.05). This increase did not occur to the same extent when CS- was
presented, as the effect of session was restricted to an escalation between
session 1 and 4 (Figure 2-7B; genotype, F1,68=0.847, p>0.05; session,
F4,68=3.465, p<0.05; genotype x session; F4,68=0.563, p>0.05; Tukey, p<0.05).
Additionally, there was an effect of session on tray entry latency with no effect of
genotype nor an interaction. (Figure 2-7E; genotype, F1,68=3.965, p>0.05;
session, F4,68=17.378, p<0.05; genotype x session; F4,36=0.535, p>0.05). By
sessions 3, 4, and 5, subjects were significantly faster at entering the tray
(Tukey, p<0.05). Collectively, these data demonstrate that both genotypes were
able to associate reward delivery in the tray with CS+ and not CS-.
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Figure 2-7: Loss of Sxc does not alter associative learning but increases CS+ approach
behavior during PCA training. A-B, Data depicts total reward tray entries during the
presentation of CS+ or CS- respectively. C-D, Total approaches toward the screen during the
presentation of CS+ or CS- respectively. E, Amount of time prior to the first reward tray entry
when CS+ is presented. F, Latency to approach CS+ during presentation. Two-way repeated
measure ANOVA; # effect of session relative to session 1, + effect of genotype independent
of session, * effect of genotype within the given session p<0.05.

Next, genotypic differences in CS+ approach behavior, a measure of
bottom-up regulation of behavior, was analyzed. Regarding CS+ approaches
during presentation (Figure 2-7C), we report main effects of session (F4,68=4.539,
p<0.05) and genotype (F1,68=5.162, p<0.05) with a significant interaction between
these variables (F4,68=6.571, p<0.05). Notably, there was an increase in CS+
approaches among MSxc rats in sessions 3, 4, and 5 relative to session 1 in
addition to an effect of genotype relative to WT within sessions 3-5 (Tukey,
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p<0.05). Regarding CS- approaches, there were main effects of session (Figure
2-7D; F4,68=4.345, p>0.05) but not genotype (F1,68=0.247, p>0.05) with an
interaction between these variables (F4,68=2.656, p>0.05). Intriguingly, WT rats
increased their approaches toward CS- by sessions 3-5 relative to session 1 and
WT rats approached CS- more than MSxc rats during session 1 (Tukey, p<0.05)
Furthermore, there was an effect of session on CS+ approach latency with no
effect of genotype nor an interaction (Figure 2-7F; Two-way ANOVA; genotype,
F1,79=1.113, p>0.05; session, F4,79=2.837, p<0.05; genotype x session;
F4,79=0.653, p>0.05). Rats approached CS+ more rapidly by sessions 4 and 5
relative to session 1 (Tukey, p<0.05). Notably, rats that did not approach CS+
had no latency measurement so they were excluded from this specific analysis.
These data demonstrate that MSxc rats displayed increased CS+ approach
behavior as PCA training progressed yet both genotypes approached CS+ faster
as training progressed.
Having established genotypic differences in CS+ approach during the PCA
training sessions, rats were then tested in an omission phase whereby CS+
approach behavior prevented the delivery of a reward. Omission is meant to test
whether the CS+ approach behavior can be inhibited due to negative
punishment, a form of top-down cognitive control (E. K. Miller, 2000). We
hypothesized that punishment would likely impact CS+ approach but not tray
entries. Indeed, tray entries when CS+ was presented (Figure 2-8A), revealed a
main effect of session (F4,68=4.780, p<0.05) with no effect of genotype
(F1,68=3.429, p>0.05) nor an interaction between these variables (F4,68=0.0296,

56
p>0.05). Notably, there was an escalation in tray entries by sessions 4 and 5
relative to session 1 (Tukey, p<0.05). A similar phenomenon occurred when CSwas presented (Figure 2-8B; genotype, F1,68=1.609, p>0.05; session, F4,68=3.582,
p<0.05; genotype x session; F4,68=0.155, p>0.05) with a small escalation in tray
entries by sessions 4 and 5 relative to session 1. Regarding CS+ approaches
during presentation (Figure 2-8C), we report a main effect of session
(F4,68=7.633, p<0.05) an effect of genotype (F1,68=6.187, p<0.05) with no
significant interaction between these variables (F4,68=1.707, p>0.05). Notably,
there was a reduction in CS+ approaches independent of genotype in sessions 3,
4 and 5 relative to session 1 (Tukey; p<0.05). This did not occur with CSapproaches (Figure 2-8D; genotype, F1,68=0.523, p>0.05; session, F4,68=0.870,
p>0.05; genotype x session; F4,68=0.723, p>0.05). The net effect of this
prolonged CS+ approach behavior in MSxc rats was a greater number of missed
rewards across all sessions (Figure 2-8E; genotype, F1,68=5.859, p<0.05;
session, F4,68=8.317, p<0.05; genotype x session; F4,68=0.832, p>0.05). The
number of missed rewards decreased by sessions 3,4, and 5 relative to session
1 (Tukey, p<0.05). Furthermore, the cumulative number of missed rewards
during omission testing was greater in MSxc rats (Figure 2-8E; t-test, t17=-2.421,
p<0.05). These data demonstrate that both genotypes continue to escalate their
tray entries and reduce approaches during CS+ presentation over the course of
omission testing, but MSxc rats have a prolonged increase in CS+ approach
behavior relative to WT which results in more missed rewards.
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Figure 2-8: CS+ approach behavior is maintained even when punished in MSxc rats
during omission testing. A-B, Data depicts total reward tray entries during the presentation
of CS+ or CS- respectively. C-D, Data depicts total cue approaches during the presentation of
CS+ or CS- respectively. E, Data depicts the number of rewards missed during the omission
testing sessions with a cumulative count presented in F. Two-way repeated measure ANOVA;
# effect of session relative to session 1, p<0.05; + effect of genotype independent of session,
p<0.05. *students t-test; p<0.05. Two-way repeated measure ANOVA; # effect of session
relative to session 1, p<0.05; + effect of genotype independent of session, *students t-test;
p<0.05. p<0.05.

Alternatively, PCA data can be expressed using the PCA score which
incorporates all dependent variables described so far (see methods for
description of the score calculation). The PCA score is on a scale of +1 to -1
which correspond to behavior being predominantly directed toward CS+ or the
reward tray respectively. These phenotypes are referred to as sign- and goaltracking respectively (Meyer et al., 2012). During PCA training, there was an
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Figure 2-9: Loss of Sxc produces an upward shift in PCA score. A-B, Data depicts PCA
scores during PCA training and omission testing, respectively. Please see methods for PCA
score calculation. Two-way repeated measure ANOVA; * effect of genotype within the given
session, p<0.05; + effect of genotype independent of session, p<0.05; # effect of session
relative to session 1 p<0.05.

effect of session (Figure 2-9A; F4,68=3.076, p<0.05) genotype (F1,68=5.925,
p<0.05) and a significant interaction between these variables (F4,36=3.147,
p<0.05). By session 3,4, and 5, MSxc rats had a significantly higher PCA score
relative to WT (Tukey, p<0.05). Additionally, the PCA score of WT rats decreased
by sessions 4 and 5 relative to session 1 whereas the PCA score of MSxc rats
was not impacted by session (Tukey, p<0.05). During omission, there were
effects of session and genotype with no interaction between these variables
(Figure 2-9B; genotype, F1,68=4.899, p<0.05; session, F4,68=4.026, p<0.05;
genotype x session; F4,68=1.183, p>0.05). Indeed, PCA score increased by
session 5 relative to session 1 independent of genotype (Tukey, p<0.05). These
data demonstrate that the PCA score for MSxc rats is shifted upward relative to
WT which corresponds to greater CS+ directed behaviors. Collectively, the PCA
and omission data demonstrate genotypic differences in stimulus-associated
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behavior which persists even when rewards are lost which is indicative of a
disruption in executive control over behavior.
One interpretation of the prolonged CS+ approach behavior in MSxc rats
during omission testing is that MSxc rats have impaired behavioral flexibility. To
test, we utilized a maze-based attentional set-shifting paradigm to test MSxc rats’
ability to flexibly adapt behavioral strategy to obtain a sucrose reward (Figure 210A, n=6-7/genotype). The impact of genotype depended on the trial (Figure 210B; Two-way ANOVA, genotype x phase: F2,22=3.78, p<0.05). Consistent with
previous data, there was no effect of genotype during the simple discrimination
phase (t11=0.348, p>0.05). However, MSxc rats needed significantly more trials
to reach criterion during the extra-dimensional shift phase (t11=0.3.83, p<0.05).
and intra-dimensional shift phase (t11=2.96, p<0.05). This phenomenon results
from a significant increase in incidence of perseverative (Figure 2-10C; t11=3.39,
p<0.01) but not regressive errors (Figure 2-10D; t11=0.86, p>0.05) made by MSxc
rats during the second and third phase of testing. These data demonstrate that
MSxc rats display behavioral inflexibility independent of disruptions in simple
associative learning due to perseveration of a behavioral strategy that is no
longer reinforced.
To further examine the degree of disrupted executive function in MSxc
rats, we employed a Kamin fear blocking paradigm which assesses rats’ capacity
to regulate attention towards stimuli while learning about threats (Figure 2-11A,
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Figure 2-10. Loss of Sxc activity impairs cognitive flexibility A, A schematic illustrating
the experimental stages of the attentional set-shifting paradigm in which the number of trials
needed to solve a novel maze task is assessed. B, The number of trials required to meet
criteria for each of the three test sessions is depicted. The impact of genotype depended on
the trial. There was no effect of genotype on day 1, which required subjects to use stimulus
discrimination (SD) to identify the arm of the maze baited with food. MSxc rats needed
significantly more trials to reach criterion on day 2, which required an extradimensional shift
(EDS) to solve the task. MSxc rats also needed more trials to reach criterion on day 3, which
required an intra-dimensional shift (IDS) to solve the task. C, On days 2 and 3, MSxc rats
displayed more perseverative errors. D, The number of regressive errors on days 2 and 3 did
not differ between WT and MSxc rats. *p<0.05 t-test.

n=8/genotype). This procedure creates conditions whereby an association
between a novel cue (Cue-B) and shock is prevented or “blocked” by copresentation of a previously established predictor of shock (Cue-A). Hence, the
presence of Cue-A eliminates the predictive value of the novel cue (Cue-B).
When exposed to Cue-B on the test day, WT rats did not display an increase
from baseline in conditioned freezing but did freeze in response to a novel Cue-D
(Figure 2-11B; F2,14=10.73, p<0.001; Tukey HSD versus baseline, p<0.05). In
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Figure 2-11. Loss of Sxc activity impairs the gating of associative processes. A,
Schematic illustrating the experimental stages of the Kamin blocking procedure. The
procedures are designed so that the co-presentation of an established shock-predictive cue
(Cue-A) will block a novel cue (Cue-B; “blocked stimulus”) from being paired with shock
during Stage 2 and, therefore, from eliciting conditioned freezing on the test day. B, Freezing
behavior during the test day as measured during baseline (BL) or following exposure to CueB or Cue-D. WT rats display conditioned freezing to Cue-D, but not to the “blocked” stimulus,
Cue-B. MSxc rats displayed similar levels of freezing to Cue-D and Cue-B, indicating impaired
Kamin blocking. C-D, Freezing behavior during the acquisition and extinction of fear
conditioning. Two-way ANOVA; *effect of cue relative to baseline Tukey p<0.05. Special
thanks to Dr. Marieke Gilmartin’s Lab for this set of experiments.

contrast, MSxc rats displayed a lack of Kamin blocking since these rats displayed
a similar amount of conditioned freezing to Cue-B and Cue-D (Figure 2-11B;
F2,14=6.94, p<0.01; Tukey versus baseline, p<0.05). This effect was not due to
genotypic differences in the acquisition (Figure 2-11C; genotype x trial:
F8,12=1.18, p>0.05; genotype main effect F1,14=1.70, p>0.05) or extinction of fear
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Figure 2-12: Loss of Sxc increases relapse vulnerability. A, Diagram depicting the
operant chamber set up and experimental design of the cocaine self-administration model.
B, Data depicts number of infusions of cocaine received during the maintenance phase
(0.5mg/kg/infusion). C, Extinction training phase whereby lever presses no longer yielded a
cocaine infusion D, Reinstatement test phase whereby a subthreshold dose of cocaine was
delivered by the experimenter (3 mg/kg I.P). Two-way ANOVA; * Effect of treatment within
genotype; +Effect of genotype within treatment, Tukey p<0.05.

conditioning (Figure 2-11D; F5,70=0.77, p>0.05; genotype main effect F1,14=0.52,
p>0.05) or in the retention of extinction memories (Figure 2-11D; F1,14=0.37,
p>0.05). These data lend further evidence towards MSxc rats having executive
dysfunction.
The maladaptive associative learning and inflexible, perseverative patterns of
behavior seen in MSxc rats are observed in a variety of human disorders
including substance abuse (Ersche, Roiser, Robbins, & Sahakian, 2008; Keiflin &
Janak, 2015; Steinberg et al., 2013). To determine whether a loss of Sxc activity
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impacts reinforced and non-reinforced drug-seeking, we employed a cocaine
self-administration paradigm which includes three main phases: selfadministration, extinction of lever responding, and reinstatement of seeking
(Figure 2-12A). Importantly, rates of cocaine self-administration did not differ
across genotype (Figure 2-12B; genotype x session: F11,264=0.816, p>0.05;
genotype: F1,24=0.052, p>0.05). Additionally, responding under extinction
conditions, whereby the lever was no longer reinforced with cocaine, did not
differ across genotype (Figure 2-12C; genotype x session: F1,24=0.611, p>0.05;
genotype: F1,24=0.005, p>0.05). However, during the cocaine-primed
reinstatement test, MSxc rats displayed higher levels of responding relative to
their last extinction trial that otherwise did not reinstate responding in WT rats
(Figure 2-12D; t11=3.26, p<0.05 WT versus MSxc during cocaine test). These
data demonstrate that loss of Sxc function does not alter self-administration of
cocaine or extinction learning. However, MSxc rats display increased
vulnerability for relapse to an otherwise sub-threshold dose of cocaine which
suggests a lack of executive control over a behavior that no longer elicits a
rewarding outcome.
Having established that loss of Sxc impairs executive function, we next
sought to determine how loss of Sxc impacts the tripartite synapse which may in
part help illuminate the observed cognitive dysfunction. In order to ascertain
molecular disruptions in the glutamate system of MSxc rats, we chose a key
component from each compartment of the tripartite synapse that Sxc has been
shown to interact with; the pre-synaptic domain, the astrocyte, and the post-
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Figure 2-13. Loss of Sxc alters components of the tripartite synapse. A, NAc protein
levels of the presynaptic protein mGluR2/3 and paired-pulse ratio. B, NAc protein levels of the
astrocytic glutamate transporter GLT-1 and 3H-D-aspartate uptake in both NAcc tissue (ex
vivo) and cultured astrocytes (in vitro), as a measure of excitatory amino acid transporter
function. C, Western blots of the postsynaptic protein GluA1 and GluA1 phosphorylated at
threonine 840 (GluA1pT840). * p<0.05, t-test.

synaptic domain. In the pre-synaptic domain, we found no difference in group 2
metabotropic glutamate receptor expression (mGluR2/3; Figure 2-13A;
n=8/genotype; t14=0.967, p>0.05) which corresponded to no change in presynaptic release probability as measured by paired-pulse ratio (Figure 2-13A).
Additionally, GLT-1 expression was unchanged in MSxc rats (Figure 2-13B;
n=8/genotype; t14=0.26, p>0.05). However, when EAAT function was measured
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by 3H-D-Aspartate uptake, MSxc NAcc tissue had significantly lower uptake
relative to WT (Figure 2-13B; n=15-18/genotype; t31=2.69, p<0.05). This
disruption was also present in cultured astrocytes (Figure 2-13B; n=1112/genotype; t21=6.61, p<0.05). Furthermore, post-synaptic changes were also
investigated; total GluA1 expression was unchanged in MSxc rats (Figure 2-13C;
n=7-8/genotype; t14=0.967, p>0.05) but there was a significant increase in GluA1
phosphorylation at threonine residue 840 (pT840; Figure 2-13C; t13=2.93,
p<0.05). These data demonstrate the presence of impaired EAAT function and
GluA1 hyper-phosphorylation in the NAcc of MSxc rats independent of changes
in pre-synaptic release of glutamate.
Given the molecular and functional changes in GluA1 and EAATs, we
hypothesized that excitatory output from the NAcc would be increased in MSxc
rats. Miniature excitatory post-synaptic currents (mEPSCs) were measured from
medium spiny neurons (MSNs n=15-17/genotype) projecting to the substantia
nigra (SN; Figure 2-14A,C) and ventral pallidum (VP; Figure 2-14B,D). The
frequency (t26=2.7, p<0.05) and amplitude (t26=2.35, p<0.05) of mEPSCs were
increased in MSxc SN MSNs which correlated with a leftward shift in intervals
and rightward shift in amplitude cumulative probability plots. Additionally,
mEPSCs were unaltered in VP MSNs (Frequency, t30=0.01, p>0.05; amplitude,
t31=0.52, p>0.05). These data suggest that loss of Sxc produces an
enhancement of synaptic strength in an efferent specific manner and
consequently highlight a role for Sxc in regulating AMPAR function and gating
excitatory output for specific neural networks.
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Figure 2-14. Loss of Sxc
enhances basal excitatory
neurotransmission. A,
Diagram depicting rhodamine
latex microsphere injection
targeting the substantia nigra
pars compacta (SNpc);
center- expression of
rhodamine fluorescent cells in
the NAcc; right- validation of
the injection site. C, Leftdiagram depicting rhodamine
latex microsphere injection
targeting the globus pallidus
(GP); center- rhodamine
fluorescent cells in the NAcc;
right- validation of the
injection site, hitting the
majority of the GP. B, Sample
traces from WT and MSxc
SNpc projecting and D, GP
projecting MSNs. (Right)
Cumulative probability plots
for inter-event intervals and
amplitude of mEPSCs
recorded from the respective
efferent. * T-test p<0.05.
Special thanks to Dr. Qingsong Liu for C-D.

Q
DISCUSSION

The purpose of these studies was to test the possibility that the acquisition
of Sxc was a key event in achieving the signaling complexity needed for
executive function and cognition in vertebrate species. We hypothesized that
disrupting Sxc function would be sufficient to disrupt glutamate
neurotransmission and produce a rat with maladaptive behavioral traits. We
found that eliminating Sxc increased the likelihood that environmental stimuli,
and previously learned associations about them, would be more likely to elicit an
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inappropriate behavioral response. Despite altering behavioral phenotypes in
PCA, set shifting, fear blocking, and cocaine reinstatement tasks, the loss of Sxc
did not disrupt exploratory behavior, basic learning and memory, or general
physiology. This suggests that the role of Sxc in cognition is discrete and
restricted to executive functions such as reversal learning, attentional gating, and
behavioral control. This degree of cognitive dysfunction in a natural environment
would likely put MSxc rats at a significant disadvantage, making them
maladapted to their environment.
Furthermore, loss of Sxc produced discrete disruptions in excitatory
signaling in the NAcc. We found that loss of Sxc broadly impaired EAAT function
in astrocytes. Additionally, AMPAR were hyperphosphorylated at residue T840
which corresponded to an enhancement in mEPSCs in the direct but not indirect
pathway from the NAcc. Notably, these changes were independent of any
change in pre-synaptic glutamate release. The significance of this pathway
specific enhancement is evidenced by the direct pathway being important for
driving motivated behavioral responses (Bromberg-Martin, Matsumoto, &
Hikosaka, 2010; Lobo et al., 2010). This may in part explain why cognitive
dysfunction was observed in MSxc rats, due to an inability to effectively gate
excitatory output in this pathway. However, more work will be needed to
determine if dampening this pathway would be sufficient to rescue the cognitive
deficits.
These findings reveal that the existence of evolutionarily new glutamaterelease mechanisms could enable the isolation and therapeutic targeting of
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signaling needed for specialized domains of brain function, such as cognition.
Indeed, there is growing evidence that compounds that increase Sxc activity
such as n-acetylcysteine have significant therapeutic potential in pre-clinical and
clinical studies of cognitive disorders such as drug addiction, binge eating
disorder, trichotillomania, and obsessive compulsive disorder (Amen et al., 2011;
J. E. Grant, Odlaug, & Kim, 2009; Hurley et al., 2016; Oliver et al., 2015; Tomko
et al., 2018). Importantly, these studies highlight the efficacy of n-acetylcysteine
and its tolerability in patients due to a lack of significant side effects which
supports the discrete role of Sxc in brain function and behavior, thus making it an
excellent therapeutic target.
The potential for Sxc to confer important benefits to brain complexity and
behavioral capabilities should be evident in the evolutionary history of
Slc7a11/xCT. The Sxc-subunit xCT first appeared some point after the
divergence of protostomes and deuterostomes (Lewerenz et al., 2013), which
indicates that Sxc is a relatively newer adaptation in animals. Our key findings
from our phylogenetic analysis were that the majority of the xCT protein coding
sequence was under significant negative selective pressure in vertebrates, and
the sequence has gained novel kinase regulatory sites. Specifically, our SLAC
analysis, which detects amino acids that were under selective pressure, found
that 70% of the amino acids had a greater degree of synonymous than nonsynonymous mutations occurring within their codons. This means that while
mutations did occur, they were more likely to encode the same amino acid. This
demonstrates that selective pressures resisted changes in the sequence, such
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that if a non-synonymous mutation were to occur, it would be rapidly removed
from the gene pool through purifying selection. In other words, the mutation
would make the organism maladapted to their environment. Importantly, the
SLAC analysis did not detect evidence of positive selective pressure, e.g. a gain
of an adaptive mutation, in the xCT sequence.
While there were no sites under positive selective pressure, further
inspection of the sequence revealed the gain of regulatory sites. The three sites
were S26, S185, and S481 and have varying degrees of conservation in
vertebrates. For example, S26 is more represented in primates than in birds,
reptiles, fish, or other mammals whereas S481 is unique to mammals. This
suggests these sites were involved in speciation, perhaps through providing
some functional advantage. However, our SLAC analysis did not conclude that
these regulatory sites were positively selected for. While advantageous
mutations are of interest, detecting them is difficult considering that synonymous
mutations and negative selection are the predominant evolutionary forces (M.
Kimura, 1968; Motoo Kimura, 1983; Kreitman, 2000). Given this, there are two
principle interpretations that can be drawn about the significance of the
regulatory sites. First, our statistical methods used to determine selective
pressure are limited by the available sequence data. While we analyzed 115
vertebrate species, there are many more species whose xCT sequence is not
known. By adding more data, it is possible that sites under positive selection
would arise. On the other hand, acquisition of these sites may have been due to
random genetic drift that just happened to become stabilized within certain
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species. With either interpretation, further work is needed to elucidate the
biological relevance of these novel regulatory sites in xCT.
Collectively, the phylogenetic signature of xCT suggests it is a
fundamental protein to vertebrates; organisms without it have maladaptive
cognitive traits. While our phylogenetic analysis failed to find evidence for
mutations that provided an adaptive advantage, this approach still revealed novel
regulatory sites that were gained during vertebrate evolution. If we can
characterize the functional relevance of these regulatory sites, we will be able to
understand their contribution to cognitive ability. Using this information, we could
investigate the possibility that polymorphisms that alter these sites make humans
more susceptible to cognitive disorders. In support, the phosphorylation of S26
has been shown to regulate Sxc function and dysregulation of this site may
contribute to the psychotomimetic effects of phencyclidine in rats, a pre-clinical
model of schizophrenia (McClatchy et al., 2016). Thus, these findings are
consistent with the possibility that disrupted function of evolutionarily new genes
expressed by astrocytes may underlie cognitive impairments.
Intriguingly, while xCT itself is a relatively recent adaptation on the
evolutionary timeline (Lewerenz et al., 2013), its ancestral homologs in
invertebrates share similar functional characteristics and suggests that it has
been critical for cognitive processing for millions of years. In support, it is
accepted that invertebrate species such as c. elegans and drosophila can learn
conditioned approach responses and are able to successfully adapt behavior in
response to changes in the environment to improve survivability (Foley,
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Marjoram, & Nuzhdin, 2017; Zhao, Khare, Feldman, & Dent, 2003). Importantly,
they express a putative xCT homolog named genderblind (gb), which has
approximately 36-45% sequence homology to mammalian xCT and contains the
essential cystine residue (C158) allowing it to dimerize to 4F2hc (Augustin,
Grosjean, Chen, Sheng, & Featherstone, 2007). The function of gb is strikingly
like mammalian xCT. Its function is to maintain extracellular glutamate which
desensitizes neuronal glutamate receptors and dampens excitatory output. Its
role in cognitive processing is to regulate how olfactory chemical stimuli influence
approach behavior. Consequently, drosophila lacking gb more readily engage in
homosexual mating behaviors due to misinterpretation of sexual olfactory stimuli,
which is inherently maladaptive (Grosjean, Grillet, Augustin, Ferveur, &
Featherstone, 2008). Furthermore, deletion of gb is not inherently fatal, which
suggests that gb/xCT have maintained a discrete role in cognitive processing for
millions of years. Thus, while xCT is considered a relatively recent adaptation, it
has maintained some of the functional and qualitative characteristics of its
ancestral homologs.
While a narrower manipulation of Sxc such as a conditional knockout in
adulthood may have been an alternative approach to investigate certain aspects
of our hypothesis, we felt the global knockout was the only way in which broad
questions about the role of Sxc in mammalian cognition could be addressed.
While an argument could be made for the observed cognitive dysfunctions being
the result of developmental perturbations, previous work from our lab
demonstrates that acute pharmacological disruptions in adulthood produced

72
similar deficits in behavioral flexibility to those seen in the MSxc rat (Lutgen et al.,
2014). Additionally, our global knockout approach is similar to what was used to
explore the functional role of the Dlg orthologs in cognitive processing in mice (S.
G. Grant, 2016). Furthermore, If the global knockout approach was not used, we
would not have learned that loss of Sxc is not inherently fatal and is void of any
obvious developmental impairments which would be suggestive of it being
involved in fundamental brain functions that support life, and consequently make
it a risker therapeutic target. Lastly, because Sxc is present in the amygdala,
hippocampus, prefrontal cortex and NAcc (Baker, McFarland, Lake, Shen, Tang,
et al., 2003; Lutgen et al., 2014), which are all brain regions involved in cognitive
processing, an acute knockdown approach in each region coupled to all of our
behavioral measures would have been laborious and it does not control for the
possibility that Sxc dependent signaling in these other brain regions could
compensate for disruption in another. Thus, our global knockout approach was
appropriate for the questions we sought to answer, which revealed that Sxc has
a discrete role in cognition and is not critical for fundamental brain functions that
sustain life.
PCA has been used to model the process by which stimuli are learned to
be predictive of a desired outcome, acquire motivational properties, and
subsequently influence behavior (Robinson et al., 2014). In canonical models of
PCA, an operant chamber is outfitted with retractable levers which serve as the
CS and are predictive of a food reward delivery. Over repeated pairings, the lever
extension triggers a conditioned approach and appetitive response to the lever

73
as it has become imprinted with the incentive and perhaps emotional value of the
food reward (Meyer, Cogan, & Robinson, 2014). A common observation is that
two distinct behavioral phenotypes emerge during training; sign tracking and goal
tracking, which correspond to the rats’ propensity to guide appetitive behavior
towards the CS or towards the reward tray, respectively. These phenotypes are
characterized by the PCA score, which is on a scale of +1 (sign tracking) to -1
(goal tracking) with an intermediate phenotype at 0 (Meyer et al., 2012). Over
repeated training, sign tracking behavior becomes the predominant phenotype,
with little to no tray entries during the presentation of the CS. A key distinction
relative to our experiments is the use of a retractable lever rather than a visual
stimulus as the CS. Notably, our WT rats over the course of training display
almost a complete lack of CS approach behavior but do increase tray entries
across training whereas MSxc rats increase CS approach in addition to tray
entries that persists even when punished for CS approach. The lack of approach
behavior in WT rats was surprising but it is consistent with reports that
demonstrate conditioned approach is reduced when the CS cannot be physically
interacted with (Cleland & Davey, 1983; Meyer et al., 2014). Because of this, our
ability to observe the degree to which the CS influences behavior in MSxc rats
relative to WT was enhanced. Furthermore, this suggests that the PCA score and
the categorization of sign- versus goal-trackers can be unreliable due to it being
heavily influenced by experimental parameters.
CS+ approach behavior exhibited by MSxc rats may be indicative of
inappropriate associative learning and an impairment in executive function.
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Importantly, reward delivery is not contingent on the rat approaching CS+. It is
possible that during the initial phases of training, MSxc rats formed an
inappropriate association between their CS+ approach behavior and reward
delivery. Given that CS+ approach continued to increase across sessions, it is
likely that MSxc rats were learning that their approach is what was causing
reward delivery. In this way, CS+ approach is viewed as a “bottom-up” driven
behavior due to the incentive and motivational value placed on CS+ by the
subject (Sarter et al., 2001; Sarter & Phillips, 2018). When CS+ approach was
punished during omission, MSxc rats continued to engage the CS+ which is
indicative of a lack of behavioral control or impaired “top-down” regulation of
behavior. The prefrontal cortex in particular is necessary when behavior needs to
be guided or altered by changes in internal or environmental circumstances, such
as when the probability of an outcome is changing (E. K. Miller & Cohen, 2001).
These findings have translational validity, as rats that display heightened CS+
directed behavior during PCA prefer cocaine over natural rewards when given a
choice (Tunstall & Kearns, 2015) and are more vulnerable to relapse when
exposed to drug-associated stimuli (Versaggi, King, & Meyer, 2016). Thus, it was
not surprising to see that MSxc rats displayed heightened cocaine-primed
reinstatement.
Impaired executive function was also observed during the attentional set
shifting and fear blocking paradigms. During set shifting, the rat must form the
association that the arm of the maze with a visual stimulus is predictive of
reward. On subsequent days the rat has to adapt a new strategy to obtain reward
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(always turn a given direction) as the visual cue is no longer absolutely predictive
of reward. Because the environmental circumstances and probability of a
rewarding outcome is changing, the executive centers such as the prefrontal
cortex are necessary to appropriately guide behavior (E. K. Miller & Cohen,
2001). Likewise, for Kamin fear blocking, the executive centers are required
efficiently direct focal attention toward environmental stimuli that are predictive of
danger while blocking out ones that are not (Diamond, 2013; Posner &
DiGirolamo, 1998). Expectedly, WT rats did not show fear to a novel stimulus
that was co-presented with a stimulus that was previously learned to be
predictive of danger. On the other hand, MSxc rats did show fear which suggests
they lack the ability to effectively gate extraneous sensory information. Given our
behavioral findings, MSxc rats appear to have impaired executive function. As a
result, environmental stimuli, and previously learned associations about them,
are more likely to elicit an inappropriate behavioral response in MSxc rats.
Importantly, MSxc rats are able to extinguish drug seeking and fear
response behavior, which may challenge the assertion that Sxc is involved in
gating how conditioned responses elicit future behavioral responses. Extinction,
by definition, is a learning phenomenon whereby responding to CSs decreases
when the outcome is omitted (Quirk & Mueller, 2008). Extinction learning has
three phases: acquisition, consolidation, and retrieval. The acquisition phase is
the initial learning phase whereby responses begin to decline due to a lack of
reinforcement. This learning is then consolidated into a long-term memory which
can be recalled during retrieval (e.g. reinstatement) to elicit a behavioral

76
response. As demonstrated by both the fear conditioning and cocaine selfadministration paradigms, there is no genotypic difference in the acquisition or
consolidation of extinction memory. The lack of genotypic difference in
acquisition of extinction may be explained by this phase being a new learning
phenomenon similar to the initial conditioning phase. Specifically, we know that
MSxc rats do no struggle with forming simple associations between CSs and
outcomes and therefore we should expect them not to struggle with extinction
acquisition. Additionally, CS responding during extinction training steadily
declines over time in both genotypes which suggests that the new extinction
memory is being remembered or consolidated.
Intriguingly, the retrieval of extinction memories is impacted by loss of Sxc,
but only under certain circumstances. In particular, retrieval of extinguished fear
memory is not impacted by loss of Sxc whereas retrieval of cocaine seeking is,
as evidenced by the increase in seeking in MSxc rats following a cocaine
challenge. This discrepancy in retrieval may exist due to the nature of the
retrieval trigger, i.e. cocaine versus a light stimulus. Specifically, it is plausible
that the cocaine rather than light stimulus has a greater impact on the already
enhanced direct pathway neurons present in the MSxc rats and thus is more
likely to facilitate the reinstatement of seeking. Further work is needed to explore
the discrepancy in the genotypic differences in extinction memory retrieval but it
highlights how discrete the loss of Sxc is, even within the same dimension of
learning. Furthermore, these extinction training phenomena suggest that Sxc is
involved in influencing how learned associations elicit changes in behavioral
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response during tasks that require active attentional or working memory
allocation.
The major technical advancements of this work are the novel transgenic
GFAP:Lck-eGFP rat to aid in studying the astrocyte transcriptome and the MSxc
rat to study the importance of Sxc function in neurophysiology and behavior.
Importantly, these animals allowed us and will hopefully allow others to advance
our knowledge of the interplay between astrocytes, glutamate signaling, neural
network activity and cognition. In support, FACS data collected from the
GFAP:Lck-eGFP rat is consistent with experiments conducted in situ to
investigate the expression of xCT in astrocytes (Ottestad-Hansen et al., 2018).
An important note is that while some xCT expression is present in the GFPsample, it is possible that we did not collect every astrocyte present in the
sample. Notably, our sorting parameters were designed to exclude neurons from
eGFP+ samples rather than isolate every astrocyte. As a result, the eGFPsample also contained a very small number of astrocytes that were not
completely disassociated from other cells.
Additionally, the GFAP:Lck-eGFP rat revealed that GFAP expression can
vary across brain regions. We observed the highest GFP expression in
subcortical areas such as the thalamus as well as in the midbrain, brainstem, and
cerebellum. The GFP signal in the neocortex, hippocampus, and striatum was
comparatively lower. This is consistent with work done in human brain samples
that demonstrate regional differences in GFAP expression, with subcortical
regions expressing more GFAP than the neocortex (Torres-Platas, Nagy, Wakid,
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Turecki, & Mechawar, 2016). While the reason underlying these differences
remains unknown, the regional differences in GFAP expression appear to be
phylogenetically conserved among rats and humans.
The molecular and cellular changes resulting from loss of Sxc, while
relatively minor, appear to be consistent with previous findings. It was surprising
to not see a change in mGluR2/3 expression or its ability to regulate pre-synaptic
release probability given previous work supporting group 2 mGluRs in relaying
Sxc dependent signals (Baker et al., 2002). However, the xCT null mutant mice
did not display changes in pre-synaptic plasticity, consistent with our findings (Y.
Li et al., 2012). Additionally, pT840/GluA1 density was increased in hippocampal
synapses of xCT knockout mice which corresponded to an increase in
spontaneous and evoked EPSCs (Williams & Featherstone, 2014). We found a
similar increase in the NAcc of our MSxc rats and established that this
phenomenon may occur in a pathway specific manner given that enhanced
mEPSCs were found only in the direct pathway.
The mechanism underlying how only the direct pathway is influenced by
loss of Sxc or how Sxc can regulate GluA1 phosphorylation remains unresolved.
We speculate that there could be differences in the proximity of Sxc to NAcc
efferents or that the neuronal receptor responsible for receiving Sxc derived
glutamate that is regulating GluA1 is differentially expressed or no longer being
activated. In support of the latter interpretation, NMDAR activation can lead to
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Figure 2-15: Model of the tripartite synapse in the NAcc. Our findings demonstrate a link
between astrocyte to neuron signaling via Sxc being a critical component of neural network
regulation and ultimately executive control over behavior. Previous work suggests Sxc
communicates through pre-synaptic mGluRs to gate synaptic release while this work
demonstrates Sxc can gate AMPA receptor signaling, likely through activation of
extrasynaptic NMDARs. This will be explored later.

dephosphorylation of T840/GluA1 (Delgado et al., 2007). Given the lateral
diffusion capabilities of NMDARs (Groc et al., 2004), they may be in a position to
receive non-synaptic glutamate signals from astrocytes. Indeed, NMDAR
activation via glutamate release from astrocytes produces slow inward post
synaptic currents (SICs). What makes SICs unique are their slow kinetics and
dependency on the proximity of an astrocyte (Fellin et al., 2004; Kovacs & Pal,
2017). Our data suggest that Sxc may signal through NMDARs to influence
GluA1, and this will be directly tested in subsequent experiments.
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Sxc and EAATs such as GLT-1 have been suggested to be strongly coregulated (Knackstedt, Melendez, & Kalivas, 2010). While it was surprising that
we saw no change in GLT-1 expression, we chose to investigate changes in Daspartate uptake, which is a more general measure of EAAT function. Not
surprisingly we saw a reduction in D-aspartate uptake in MSxc tissue and cells,
which is consistent with the co-regulation hypothesis of Sxc and EAATs. A
limitation of this study is that only a single concentration of D-aspartate was
used. Future experiments will be aimed at investigating changes in transport
kinetics which may help elucidate the nature of this apparent reduction in
function.
Understanding brain function is one of the greatest challenges in modern
science; it also has among the highest potential to reduce the burden of human
disease. However, a paradigm shift in neuroscience may be needed for dramatic
advances in understanding the human brain. Given our findings, perhaps the
description of astrocytes as mere metabolic support cells is emerging as an
example of an overly simplistic and possibly inaccurate perspective that is
limiting the progress of modern neuroscience research. Incorporating advances
and approaches from artificial intelligence, evolution, and other disciplines have
the potential to transform efforts to understand the healthy and diseased brain to
uncover novel therapeutic strategies. Our data are consistent with the possible
organization of glutamate signaling whereas evolutionarily newer glutamaterelease mechanisms expressed by astrocytes, e.g. Sxc, have a restricted,
specialized set of functions in regulating neural circuits and cognition. Hence,
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further work into evolutionarily newer forms of intercellular signaling may enable
the selective manipulation of discrete domains of brain activity, such as cognition
and better equip us to treat the brain’s most debilitating diseases.
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CHAPTER III:
ENDOGENOUS FACTORS THAT REGULATE SXC

INTRODUCTION
The previous chapter establishes Sxc as a critical component in cognitive
processing. Sxc appears to be necessary for gating the influence that
environmental stimuli and their learned associations have on eliciting an
appropriate behavioral response. Considering this, the next question to address
is how Sxc is involved in this process. Specifically, there is a need to determine
what molecular factors are influencing Sxc function and the mechanisms
underlying Sxc regulation of neural circuits in a manner relevant for cognitive
control.
When we consider the NAcc tripartite model, incoming stimulus
information is largely conveyed by the afferent neurons which transmit their
information to the direct pathway to drive a behavioral output. An unresolved
question is how and when astrocytes are recruited for the regulation of neural
circuits. Theoretically, if the complexity of the incoming information is high, neural
networks may recruit astrocytes to aid in processing of information to increase
efficiency and expedite an appropriate response. If this is true, then perhaps
neurons release a factor signaling to astrocytes that they are needed to assist
with cognitive processing.
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Figure 3-1: Conservation
of xCT consensus
phosphorylation
sequences among
vertebrates. Sequences
were deemed conserved
so long as the base
consensus sequence was
retained; R-X-X-S and S-XX-X-S for CaMKII/MSK1
and GSK-3β respectively.

The previous chapter established that xCT acquired novel kinase
regulatory sites during vertebrate evolution which may have allowed neural
factors to signal through astrocytes and regulate Sxc function which in turn,
allowed Sxc to impact encoding of environmental information. There are three
proposed regulatory sites on the human sequence of xCT that are conserved in
rats: S26, S185, S481. These serine residues match consensus sequences for
CaMKII/MSK1 and GSK-3 (Figure 3-1). Intriguingly, the degree of conservation
among these sequences is different, with the GSK-3β site having a 92%
conservation rate and the two MSK1 sites having rates of 57% and 39% (S26
and S481 respectively). Furthermore, the emergence of S26 occurs in some
reptiles and most birds, but expression falls in mammals but becomes stoic in
primates. Likewise, S481 emerges first in mammals and is present in all
primates, suggesting that these regulatory sequences were recently acquired
and may be downstream targets of a variety of intracellular signaling cascades
triggered by multiple neural factors. This leads to the questions; which neural
factors regulate Sxc and what are the functional changes resulting from these
biophysical adaptations?
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In order to investigate the contribution of neural factors to the function of
Sxc, we chose to explore three possible sources of influence: the post-synaptic
neuron, pre-synaptic neuron, and hormones and select a molecular factor that
might target one of these sites. First, the post-synaptic neuron could be
contributing to the regulation of Sxc. Recent studies support a role of
endocannabinoid mobilization in striatal efferents which act on the cannabinoid-1
receptor (CB1R) in adjacent astrocytes which drives glutamate release at homotypic, hetero-synaptic circuits. This glutamate activates neuronal mGluRs and
consequently enhances synaptic glutamate signaling and thus output power
(Martin et al., 2015). Importantly, the mechanism that releases glutamate from
astrocytes in this study was not investigated, which questions whether Sxc is
involved. Furthermore, CB1R activation has been shown to regulate GSK-3β
which targets S185 of xCT (Ozaita, Puighermanal, & Maldonado, 2007).
Regarding the pre-synaptic terminal, the neuropeptide PACAP1-38
(shorthand PACAP) is co-released with glutamate and can influence the
expression and function of glutamate transporters in astrocytes such as Sxc
(Kong et al., 2016; Resch et al., 2014) and GLT-1 (Figiel & Engele, 2000) in
addition to neuronal NMDARs and AMPARs (Toda & Huganir, 2015; Yaka, He,
Phamluong, & Ron, 2003). However, the rate in which PACAP influences Sxc
and GLT-1 is slow, as it takes days of application in vitro to see changes in
expression and function. Rapid effects of PACAP on Sxc function remain to be
studied and these findings would have important implications for the potential to
rapidly influence neural networks. Furthermore, PACAP has been shown to
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influence MSK1, which targets S26 and S481 of xCT (Butcher, Lee, Cheng, &
Obrietan, 2005).
Lastly, hormones could potentially be influencing Sxc function. A recent
study has suggested that Sxc is a resilience factor for stress by observing that a
reduction in the expression of xCT was present in the ventral hippocampus of
mice exposed to chronic restraint stress for 21 days. Remarkably, when nacetylcysteine was orally administered during the last 3 days of stress exposure,
xCT expression was restored and social interaction behavior improved (Nasca et
al., 2017). This finding calls into question whether stress related hormones such
as corticosterone are influencing the expression or function of Sxc. Furthermore,
glucocorticoids have been shown to activate MSK1 and drive its translocation
from the nucleus to the cytosol which would put it in position to regulate S26 or
S481 of xCT.
Conducting a series of in vitro experiments using cultured astrocytes, we
investigated the ability for endocannabinoid, PACAP, and corticosterone
signaling to influence the function of Sxc through cystine uptake or cystineevoked glutamate release. These findings will help illuminate how neural and
hormonal factors regulate astrocytes through modulating Sxc function and in turn
regulate neural circuits to encode incoming stimulus information.
MATERIALS AND METHODS
Cell Culture: Astrocyte cultures were generated from postnatal day-3 rat pups.
The striatum was dissected and dissociated using 0.25% trypsin EDTA (Gibco)
and cultured in 75 cm2 flasks in a humidified incubator at 37°C under 95% O2 5%
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CO2 in Eagles minimum essential medium (Gibco) supplemented with 5% fetal
bovine serum/5% horse serum (Atlanta Biologicals), Glutamax (Gibco), and
antibiotics/antimycotics (Gibco). To remove debris and non-astrocytic glia, flasks
were agitated, and the resulting mono-cell layer was resuspended with 0.25%
trypsin EDTA. Cells were counted by hand via a cytometer and seeded in 24-well
plates coated with poly-D-lysine and laminin at a density of 200,000 cells per
well.
Glutamate release assay: Striatal astrocytes (DIV14) were incubated for 30
minutes at 37oC in Na+-free buffer containing the following: 116 mM choline
chloride, 13.4 mM MgSO4, 1.68 mM KH2PO4, 2.34 mM CaCl2, 5.49 mM
dextrose, 11.9 mM HEPES, 0.2% choline bicarbonate, titrated to pH: 7.4 with
CeOH. This buffer was used to prevent Na+-dependent uptake of glutamate. Lcystine (12.5 or 200 M) were applied to drive cystine-glutamate exchange by
Sxc. These concentrations were chosen because they approximate the required
cystine for Km and Vmax of xCT transport. Corticosterone-HBC and PACAP
treatments were applied for 30 minutes at which point media samples (100 l)
were collected for subsequent glutamate analysis using HPLC. Cells were then
dissolved in 0.5% SDS and total protein for each well was quantified using the
BCA method.
Glutamate HPLC: The concentration of glutamate was quantified by comparing
peak areas from samples and external standards using HPLC coupled to
fluorescence detection. A 10 l sample underwent pre-column derivatization with
orthophthaladldehdye (OPA) in the presence of 2-mercaptoethanol using a
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Shimadzu LC10AD VP autosampler. Chromatographic separation was achieved
using a Kinetex XB C-18 (50 x 4.6 mm, 2.6 m; Phenomenex) and a mobile
phase consisting of 100 mM Na2HPO4, 0.1 mM ethylenediaminetetraacetic acid
(EDTA), 10% acetonitrile at a pH of 6.04. Glutamate was detected using a
Shimadzu 10RF-AXL fluorescence detector with an excitation and emission
wavelength of 320 and 400 nm, respectively. Glutamate content for each sample
was normalized to total protein in the respective well and depicted as a net
change from baseline. The data was fit using the Michaelis-Menten equation to
determine Km and Vmax.
14C-L-Cystine

Uptake Assay: Cultures were rinsed with 1x HBSS media prior to

application of vehicle [1x HBSS, 1% FBS, 0.1% dimethylsulfoxide (DMSO),
200nM 14C-L-Cystine] or WIN55 [1x HBSS, 1% FBS,1µM WIN55,212, 200nM
14C-Cystine]

treatment solutions. Plates were incubated at 37oC for 20 minutes

followed by three rinses with 1x HBSS. Cells were lysed with 300µL of 0.5%
sodium dodecyl sulfate (SDS) per well. A 200µL aliquot was taken for scintillation
count and a 25µL aliquot was taken for BCA assay.
Data analysis: All experiments were analyzed using a two-way ANOVA with a
Tukey post-hoc test. Data are presented as mean ± SEM.
RESULTS
An in vitro radiolabeled cystine (14C-L-cystine) uptake assay was utilized
to ascertain the sufficiency for a CB1R agonist (WIN55,212) to rapidly enhance
Sxc-dependent cystine uptake (Figure 3-2; n=11-12/genotype). A two-way
ANOVA revealed a main effect of treatment (F1,42=7.225, p<0.05), genotype
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Figure 3-2: CB1R
agonism enhances Sxc
dependent cystine
uptake. Data depicts
mean ± SEM radioactivity
of WT and MSxc cell
samples treated for 20
minutes with radiolabeled
L-cystine with or without
the CB1R agonist
WIN55,212. L-cystine
was applied at a
concentration of 200 nM.
Two-way ANOVA, Tukey
post-hoc test; # effect of
genotype within
treatment; *effect of
treatment within
genotype p<0.05.

(F1,42= 1073.739, p<0.05), with a significant interaction between these variables
(F1,42= 7.475, p<0.05). Post-hoc tests revealed a significant increase in

14C-L-

cystine uptake in WIN55,212 treated WT but not MSxc cells (Tukey, p<0.05).
These data demonstrate that CB1R agonism rapidly enhances Sxc dependent
cystine uptake within 20 minutes and loss of Sxc greatly reduces cystine uptake.
Next, an in vitro cystine-evoked glutamate release assay was conducted
to determine the effect of PACAP application on extracellular glutamate in WT
and MSxc cells (Figure 3-3; n=6-12/genotype). One cystine concentration were
used in this experiment, 12.5 µM, which approximates the Km of Sxc mediated
transport. A two-way ANOVA revealed a main effect of genotype (F1,40=
275.645, p<0.05) and treatment (F3,40= 4.492, p<0.05) with a significant
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Figure 3-3: PACAP
dose dependently
increases
glutamate release
via Sxc. Data
depicts mean ± SEM
extracellular
glutamate evoked by
a 30-minute cystine
(12.5 µM) and
PACAP1-38
treatment. Two-way
ANOVA, Tukey posthoc test; # effect of
genotype within
treatment; *effect of
treatment within
genotype p<0.05.

interaction between these variables (F3,40= 4.003, p<0.05). There was a large
reduction in extracellular glutamate in MSxc cells within each PACAP treatment
group (Tukey, p<0.05). Within WT cells, PACAP dose-dependently increased
extracellular glutamate (0 nM vs 10 and 100 nM; Tukey, p<0.05). This
phenomenon did not occur in MSxc cells (Tukey, p<0.05). These data
demonstrate that PACAP can rapidly increase extracellular glutamate in an Sxcdependent manner and that loss of Sxc greatly reduces extracellular glutamate.
Lastly, an in vitro cystine-evoked glutamate release assay was conducted to
determine the effect of corticosterone application on extracellular glutamate in
WT cells (Figure 3-4; n=3-4/treatment). Two cystine concentrations were used in
this experiment: 12.5 and 200 µM, which estimate the Km and Vmax of Sxc
mediated transport, respectively. A two-way ANOVA revealed an interaction
between treatment and cystine (F2,16= 3.762, p<0.05). There was a dose
dependent increase in extracellular glutamate resulting from corticosterone
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Figure 3-4:
Corticosterone
enhances glutamate
release form
astrocytes in a
cystine-dependent
manner. Data depicts
mean ± SEM
extracellular
glutamate evoked by
a 30-minute cystine
and corticosterone
treatment. Two-way
ANOVA, Tukey posthoc test; *effect of
treatment within
cystine treatment
p<0.05.

treatment (0 vs 100 nM) within the 12.5 µM cystine treatment group (Tukey,
p<0.05). This phenomenon did not occur in the 200 µM cystine treatment group
(Tukey, p>0.05). These data demonstrate that corticosterone significantly
enhances cystine-evoked glutamate release when rates of uptake are near the
Km but not Vmax of transport.
DISCUSSION
These data establish three potential sources of influence for Sxc function:
the pre-synaptic neuron, post-synaptic neuron, and hormonal milieu. We chose
to investigate the endocannabinoid, PACAP, and corticosterone signaling due to
the likely possibility that they are influencing one or more of the putative
regulatory sites on xCT: S26 and S481 which are regulated by MSK1 and S185
which is regulated by GSK-3β. Furthermore, these experiments provide the first
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evidence that PACAP, corticosterone and CB1R agonism can rapidly influence
Sxc function. Given the predicted kinase regulatory sites on xCT via MSK1 and
GSK3, there is a clear need to investigate how these factors might be influencing
these kinases. Additionally, the extent to which these factors influence behavior
through Sxc remain to be studied, but given the findings in the MSxc rat, it is
possible that these factors can modify how astrocytes regulate neural networks
and behavior.
The impact of corticosterone on Sxc function appears to be specific to the
efficiency of transport or Km given that glutamate release was only impacted at
12.5 µM L-cystine. Effectively, this means that Sxc can expel more glutamate at
lower cystine concentrations. Unfortunately, it is not currently understood how
Sxc does this, but it may be through a biophysical adaptation caused by
phosphorylation of the xCT subunit which increases the transport probability of
cystine and glutamate. Furthermore, we did not control for effects independent of
Sxc, as a negative control such as sulfasalazine treated or MSxc cells were not
treated with corticosterone. Future experiments will be aimed at understanding
whether the effects seen here are Sxc dependent and if so, how corticosterone
may change the phosphorylation of xCT. Given the link between glucocorticoid
signaling and activation of MSK1 (Beck et al., 2013), we hypothesize that S26 or
S481 are likely impacted by corticosterone.
The impact of corticosterone on Sxc function may have implications for
cognitive control as stress can influence performance in behavioral flexibility
tasks (Hurtubise & Howland, 2017). Intriguingly, the intensity of the specific
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stress paradigm can differentially impact performance in set shifting or reversal
learning. Mild stressors such as a brief 30-minute restraint or being placed on an
elevated platform prior to testing would improve reversal learning suggesting that
stress in this context is providing an adaptive advantage. Conversely, repeated
exposure to stressors for a week or more broadly impaired set shifting and
reversal learning which suggests that stress over prolonged periods of time
produces a maladaptive behavioral phenotype. Because Sxc has been linked to
stress resiliency (Nasca et al., 2017) it is feasible that stress hormones such as
corticosterone could be affecting Sxc function and consequently changing the
behavioral response to acute and chronic stressful stimuli. Future work should be
aimed at investigating this link.
Given our experimental design, we cannot determine the effect of CB1R
agonism on Sxc kinetics. At best, due to the use of a low concentration of Lcystine (1 µM), we can speculate that the increase in L-cystine uptake seen with
CB1R agonist treatment is indicative of a reduction in Km of Sxc transport. Much
like with the effect of corticosterone, how CB1R agonism increases the efficiency
of Sxc transport is unknown but likely involves a phosphorylation event.
Importantly, this finding illuminates Sxc as one of the mechanisms that is
involved in CB1R-dependent glutamate release from astrocytes. The finding that
CB1R signaling in astrocytes leads to pathway specific regulation of neural
circuits via glutamate release mirrors our findings in the first chapter
demonstrating that loss of Sxc induces a pathway specific enhancement of
excitatory output from the NAcc (Martin et al., 2015). While this paper did not
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investigate the glutamate release mechanism downstream of CB1R, we can
speculate that one of the targets may be Sxc. Furthermore, CB1R activation has
been shown to regulate GSK-3β which targets S185 of xCT (Ozaita et al., 2007).
Given this, future experiments aimed at understanding the link between Sxc and
the endocannabinoid system are warranted and may reveal how
endocannabinoids influence astrocytes to regulate behavioral control.
Like corticosterone, the endocannabinoid system can produce effects on
performance in behavioral flexibility tasks, which are suggestive of its link to Sxc
function. For example, when the CB1R antagonist AM251 is administered at low
doses prior to a spatial to visual cue or visual cue to spatial shift in response
strategy, the number of perseverative errors committed were reduced.
Intriguingly, higher doses did not produce this effect. Furthermore, when the
CB1R agonist HU-210 is administered, there are dose-dependent effects on
perseverative errors with low doses reducing and higher doses increasing these
errors. Intriguingly, the low dose of HU-210 increased the number of regressive
errors made when shifting towards a spatial cue which suggests latent inability to
maintain the new behavioral strategy after sufficient successful trials. This may
be due to the difficulty in shifting away from the visual cue which has both visual
and tactile qualities and makes it a more salient cue relative to spatial cues (Hill,
Froese, Morrish, Sun, & Floresco, 2006). Thus, the potential for stimuli and the
learned associations about them to influence behavior is in part determined by
endocannabinoid signaling. An important follow up experiment will involve
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manipulating the endocannabinoid system in WT and MSxc rats to determine the
necessity of Sxc in these behavioral changes.
Lastly, the finding that PACAP dose-dependently and rapidly enhances
Sxc-dependent cystine-evoked glutamate release from astrocytes mirrors
previous findings that long-term incubation increases Sxc expression and
function (Kong et al., 2016; Resch et al., 2014). The rapid nature of this
enhancement is critical, since for PACAP to rapidly influence behavior, the
signaling mechanism needs to be able to quickly modulate Sxc function. Again,
we speculate that this rapid regulation likely comes in the form of a
phosphorylation event, possibly at one of the serine residues. Notably, there is a
link between PACAP signaling and regulation of MSK1 which targets S26 and
S481 of xCT (Butcher et al., 2005). Future experiments will investigate the
intercellular signaling pathway that links PACAP receptors and Sxc.
The ability for PACAP to influence cognitive control remains
understudied. What is currently known about the influence of PACAP on
instrumental behaviors comes from a comprehensive behavioral battery
conducted on PACAP KO mice (Hattori et al., 2012). In this study there were
remarkable increases in locomotor activity and social interaction but no
discernable differences in working memory tasks such as forced alternation and
left-right discrimination. However, there was an increase in the number of
revisiting trials during a radial arm maze task only when the delay period in
between trials was high. Unfortunately, the authors did note that some PACAP
KO mice died during this test due to food restriction which may have influenced
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the outcome. Because of the limitations of the species used, a more direct
investigation of the ability for PACAP signaling to regulate cognitive processing in
rat is required.
Collectively, these data establish three molecular factors are influencing
Sxc function. The next question that needs to be resolved is what are the
mechanisms underlying how neural factors signal through astrocytes and
neurons to coordinate neural circuits in a manner relevant for cognitive control?

.
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CHAPTER IV:
THE NEUROPEPTDE PACAP COORDINATES NEURON-ASTROCYTE
GLUTAMATE SIGNALING IN THE NUCLEUS ACCUMBENS CORE TO
ATTENUATE DRUG SEEKING

INTRODUCTION
The previous chapters have established the complexity of intercellular
communication in the brain and how the emergence of astrocytes and their ability
to release glutamate may have been a critical component involved in mammalian
cognition. However, our findings up until this point have been lacking insight into
how glutamate signals from astrocytes are encoded by neurons to modify
behavior. While the previous chapter suggests that neural and hormonal factors
have the capability of influencing Sxc function in vitro, there is a disconnect
between the production of this signal and the signal transduction mechanism that
alters neural network activity in vivo. The importance of neuron-astrocyte-neuron
communication may be to encode when astrocytes are required for processing of
complex information to elicit an appropriate behavioral response. Effectively, this
grants neurons the ability to influence astrocyte function and consequently
regulate adjacent synapses to either enhance or inhibit excitatory output and
behavioral action. Thus, the goal of the following experiments was to investigate
how an endogenous neuronal factor regulates Sxc within astrocytes and
consequently alters neuronal activity and contributes to cognitive processing.
PACAP1-38, (shorthand PACAP) is a particularly interesting factor because
of its ability to broadly regulate the glutamate system. Specifically, PACAP has
been shown to regulate the expression and function of Sxc and GLT-1 as well as
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AMPARs and NMDARs (Figiel & Engele, 2000; Kong et al., 2016; Resch et al.,
2014; Toda & Huganir, 2015; Yaka et al., 2003) . Additionally, PACAP levels
decrease in the aging brain which correlates with a reduction in cognitive function
(Han et al., 2017). However, there are important questions about a potential link
between these two outcomes; is it possible for changes in astrocytic glutamate
transport to alter post-translational modification of neuronal glutamate receptors
and consequently influence excitatory output and cognitive control?
In support of this link, our data in conjunction with others, have established
signaling mechanisms involving Sxc and their impact on neuronal signaling and
behavior. Sxc can signal through extrasynaptic glutamate receptors within the
pre- and post-synaptic domain. In the pre-synaptic domain, Sxc signals through
group 2 mGluRs which are Gαi coupled and when activated, attenuate the
opening of voltage-gated Ca2+ channels consequently preventing vesicular
release of glutamate or dopamine (Baker et al., 2002). Post-synaptically, Sxc
influences AMPAR function through diminishing the phosphorylation of T840 of
GluA1 which is thought to either reduce ion conductance or reduce synaptic
localization of AMPAR (Williams & Featherstone, 2014). Although, the
mechanism linking dephosphorylation of AMPAR with Sxc activity has not been
demonstrated, T840 is decreased by NMDAR activation (Delgado et al., 2007).
Given that NMDARs can receive extrasynaptic glutamate signals, it is possible
that Sxc may be communicating through these receptors to regulate AMPARs.
Furthermore, PACAP signaling in neurons dephosphorylates T840 and this
phenomenon is dependent on NMDAR activation (Toda & Huganir, 2015). Thus,
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we hypothesize that PACAP may have independent signaling mechanisms in
neurons and astrocytes that are linked by glutamate release via Sxc to regulate
GluA1.
Considering the link between PACAP, Sxc, NMDARs, and AMPARs, how
can these components interact in a way to alter behavior? Importantly, Sxc
expression declines following withdrawal from cocaine (Baker, McFarland, Lake,
Shen, Tang, et al., 2003), nicotine (Knackstedt et al., 2009), and opioid (Alshehri,
Hakami, Althobaiti, & Sari, 2018) intake which produces a drop in extrasynaptic
glutamate. This could cause a disinhibition of GluA1 T840 dephosphorylation
which in turn could enhance neural outputs in a pathological manner. Consistent
with this, chapter 2 illustrated how loss of Sxc function caused a pathway specific
enhancement of the direct pathway from the NAcc which has been linked to drug
seeking behavior (Lobo et al., 2010). Importantly, the mechanism underlying this
reduction in expression is unknown. One possibility is that a neural factor could
be regulating Sxc expression and upon cessation of drug consumption, the factor
becomes impaired which produces the effect on Sxc. It is possible that PACAP
signaling may become dysregulated because of substance abuse, but no
evidence exists at this time. However, given the importance of glutamate
signaling in the NAcc for the reinstatement of drug seeking and the sufficiency of
Sxc to attenuate it, we determined that investigating PACAP signaling in this
brain region would be appropriate.
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Thus, we tested the hypothesis that PACAP enhances Sxc function and
coordinates the reception of its glutamate signal in neurons to regulate neural
networks and consequently drug seeking behavior in the NAcc.
MATERIALS AND METHODS
Chemicals: Unless noted, common chemicals and reagents were obtained from
Sigma Aldrich.
Animal care and usage: Male Sprague Dawley rats were used for these
experiments. Housing conditions and experimental protocols were approved by
Institutional Animal Care and Use Committees at the Medical College of
Wisconsin or Marquette University, and were carried out according to the US
National Institutes of Health guidelines.
Creation of GFAP:Lck-eGFP transgenic rats: The Sleeping Beauty (SB)
transposon transgenesis method(Geurts et al., 2010) was used to produce
transgenic rats on the Sprague Dawley (Crl:SD) background. Briefly, a GFAP
promoter-driven fusion between the plasma membrane targeting myristolation
domain of the mouse LCK protein fused to eGFP (Benediktsson et al., 2005) was
synthesized (GeneArt) and cloned into a SB transposon vector. The transposon
plasmid was co-injected with a source of SB100X transposase mRNA into the
pronucleus of fertilized Crl:SD embryos. A breeding colony was established
harboring a single copy of the transgene inserted on rat chromosome 13
enabling robust eGFP expression. To confirm expression in situ, a rat was deeply
anesthetized and transcardially perfused with 4% paraformaldehyde. The brain
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was extracted and sliced at 100 µm and GFP signal was visualized using
standard fluorescence microscopy.
Creation of MSxc rats: Zinc-finger nucleases (ZFNs) were designed targeting
the second exon sequence
(TGCTAGCTTTTGTTCgagtcTGGGTGGAACTGCTG) to produce small deletions
of a limited number of base pairs in the Slc7a11 gene, where capital letters
represent binding sites for the individual ZFN monomers, on opposite strands.
ZFNs were injected into the pronucleus of Sprague Dawley (Crl:SD) rat embryos
by pronuclear microinjection of in vitro-transcribed encoding messenger RNAs
and the resulting offspring were screened for mutations using a Cel-1 assay and
validated by Sanger sequencing as previously described (Geurts et al., 2010)
and resulting in single-step, whole-animal disruption of Slc7a11 (MSxc rats).
Deletion of 39 consecutive base pairs
(GAGGTCTTTGGTCCCTTGCTAGCTTTTGTTCGAGTCTGG) of exon 2 was
confirmed by Sanger sequencing.
Tissue Dissociation for FACS: NAcc tissue was dissected from male GFAPlck-eGFP or WT Sprague Dawley rats and placed into ice-cold Hanks´ Balanced
Salt Solution without Ca2+ or Mg2+. Tissue was mechanically and enzymatically
dissociated to obtain single-cell suspension using Neural Tissue Dissociation Kit
- P (Miltenyi Biotec). 1% BSA, 1mM EDTA and 12.5 U/ml DNase I were added to
reduce cell clustering. Cells were incubated with 3 µM Calcein Violet 450 AM
Viability Dye (eBioscience) on ice for 10 minutes to stain live cells. An aliquot
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from each cell suspension was used to determine relative gene expression in
sorted and unsorted (total) cells.
Flow Cytometry: FACS analyses were performed using FACSDiva software
6.1.3 (BD Biosciences). Control samples (tissue obtained from rats lacking the
GFAP:Lck-eGFP transgene) were analyzed first to identify the range of
endogenous or background fluorescence intensity. In addition, the gating
parameters of the flow cytometer were set to isolate live, eGFP+ cells from
cellular debris, and cell doublets. Note, the eGFP- samples contain all tissue
excluded from the eGFP+ sample and would be expected to include eGFP- cells,
cell doublets, fragmented cells, and potentially eGFP+ cells that were not
excluded due to the use of strict gating parameters or incomplete cellular
disassociation.
RNA amplification and Reverse Transcription: FACS samples were
centrifuged (170xg, 5 min) and the supernatant was carefully extracted. Cells
were lysed using the cell lysis solution provided within the cDNA Synthesis from
Cell Lysates kit (Lucigen). This kit was used as per the manufacturer’s
instructions to amplify the RNA and reverse transcribe to cDNA for use in PCR or
qPCR. Briefly, a T7 RNA polymerase promoter was annealed to the RNA and
was reverse transcribed using MMLV reverse transcriptase. In vitro transcription
was performed, and the RNA product was treated with DNAse and purified using
the RNA Clean and Concentrator kit (Zymo). The RNA was then incubated at
70oC and rapidly cooled to 4oC. A final reverse transcription step yielded cDNA
for use in downstream applications.
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RT-PCR: PCR was conducted using GoTaq DNA polymerase (Promega). Primer
sequences were as follows: Slc7a11 (xCT) forward- 5’ AGG GCA TAC TCC AGA
ACA CG 3’; Slc7a11 reverse- 5’ TTT AGT CCC ATC AGG TCG TTG 3’; GAPDH
forward- 5’ CTC CCA TTC TTC CAC CTT TGA 3’; GAPDH reverse- 5’ ATG TAG
GCC ATG AGG TCC AC 3’; GFAP forward - 5’ GCA GGT GAG GAA GAA ATG
GA 3’; GFAP reverse - 5’ TAC GAT GTC CTG GGA AAA GG 3’; RbFox3 forward
- 5’ ATC ATA CCA TCG GCC CCA CA 3’; RbFox3 reverse - 5’ GTG AAG CGG
CTG TAC CCT CC 3’; ADCYAP1R1 forward – 5’ ATT CTT TCT CCC TCC CCT
GA 3’; ADCYAP1R1 reverse – 5’ TGG AGT ACC AAG GGC TGA AC 3’; VIPR1
forward – 5’ AGG GAA AGG ACA GAG CAA CC 3’; VIPR1 reverse - 5’ GGC
CTC TAC CAG GAC TTT CC 3’; VIPR2 forward – 5’ GTG CTA CAA GCC CTG
GTG TC 3’; VIPR2 reverse – 5’ GGT CAC GCC TAG TGG TTG AT 3’; PACAP
forward - 5′ AAC CCG CTG CAA GAC TTC TA 3′; PACAP reverse- 5′ CTT TGC
GGT AGG CTT CGT TA 3′.
Western Blotting: NAcc tissue samples obtained from adult WT and MSxc rats
(i.e., > 90 days old) underwent mechanical homogenization in a sucrose-based
buffer (300 mM sucrose, 10 mM Tris-HCl, pH 7.4) containing protease and
phosphatase inhibitors (Thermo Fisher Scientific). Protein concentration for each
whole cell lysate sample was determined via the bicinchoninic acid assay (BCA).
Protein (10 g) was resolved in a 7.5% polyacrylamide gel and wet transferred to
Immobilon PVDF membranes (EMD Millipore). Membranes were immersed for
one hour in blocking buffer (LiCOR) prior to overnight application at +4°C with a
primary antibody: rabbit anti-pT840 GluA1 (Abcam, 1:3,333), mouse anti-GluA1
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(EMD Millipore, 1:1000), rabbit anti-S897 GluN1 (Abcam, 1:1000), and mouse
anti GluN1 (Abcam, 1:1000). Secondary antibodies (LiCOR) goat anti-rabbit IR
680 DYE (1:15000) donkey anti-mouse IR 800 DYE (1:20,000) were applied for 1
hour at room temperature prior to imaging (Odyssey Fc Imaging System,
LiCOR). Band intensity was quantified using LiCOR Image Studio software and
the resulting data are presented as the target protein band intensity divided by
the reference protein band intensity.
Cell Culture: Astrocyte cultures were generated from postnatal day 3 rat pups.
Briefly, the striatum was dissected and dissociated using 0.25% trypsin EDTA
(Gibco) and cultured in poly-D-lysine and laminin treated 75cm2 flasks in a
humidified incubator at 37°C under 95% O2 5% CO2 in Eagles minimum essential
medium (Gibco) supplemented with 5% fetal bovine serum/5% horse serum
(Atlanta Biologicals), Glutamax (Gibco), and antibiotics/antimycotics (Gibco). To
remove contaminating glia and dead cells, the flasks were agitated, and the
resulting mono-cell layer was resuspended with 0.25% trypsin EDTA. Cells were
counted by hand via a cytometer and seeded in 24-well plates coated with polyD-lysine and laminin at a density of 200,000 cells per well.
D-Aspartate Uptake Assay: Striatal astrocytes (DIV14) were incubated for 30
minutes at 37oC in HEPES buffered Hanks Balanced Salt Solution. A range of Daspartate concentrations (0, 12.5, 50, 200, 800 µM) were applied to drive uptake
Vehicle saline or PACAP (100 pmol) were concurrently applied for 30 minutes. A
100 μL media sample was taken for HPLC analysis. Clearance was quantified by
subtracting the concentration of D-aspartate left in the media from the known
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input concentration. Cells were then dissolved in 0.5% SDS and total protein for
each well was quantified using the BCA method.
Glutamate/Aspartate HPLC: Glutamate and aspartate content was measured
using fluorescence detection on an isocratic HPLC system (Shimadzu). A 10 μL
sample underwent pre-column derivatization with orthophthaladldehdye (OPA) in
the presence of 2-mercaptoethanol. Samples were resolved with a Kinetex XB C18 (50x4.6mm, 2.6μm; Phenomenex, Torrence, CA) and 100mM Na2HPO4,
0.1mM Ethylenediaminetetraacetic acid (EDTA), 10% Acetonitrile, pH: 6.04
mobile phase. Peaks areas were quantitated in Shimadzu VP client software
compared to known standards. Glutamate and aspartate content for each sample
was normalized to total protein in the respective well.
Cocaine Self-Administration: Rats were trained to self-administer cocaine (0.5
mg/kg/inf, IV; 6 hr/day) or saline under a fixed ratio one schedule of
reinforcement for 12 daily sessions. Rats then underwent a two-week abstinence
period during which time they underwent stereotaxic surgery for cannula
implantation targeting the NAcc (6o, +1.2 mm anterior-posterior, +2.2 mm mediallateral, -4.8 mm dorsal-ventral; injectors projected 2 mm past the end of the
cannula). One week following recover, rats underwent extinction training
sessions, which were identical to the self-administration sessions except lever
presses resulted in saline infusions. Once rats met the extinction criterion of
fewer than 15 presses/day, reinstatement testing was conducted. Reinstatement
testing involved pretreatment with a high dose of cocaine (10 mg/kg, IP) in
addition to a bilateral infusion of vehicle (saline or DMSO), PACAP1-38 (100
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Figure 4-1: Schedule for long
access cocaine selfadministration paradigm.

pmol/side), RO-25-6981 (2 µg/side), SKF 81297 (0.125μl/min, 0.5μl total volume,
3 µg/side) ten minutes prior to testing and recording lever pressing for 2 hours.
Rhodamine Tracer injection: Wild type and Sxc rats were anesthetized with
ketamine/xylazine and underwent stereotaxic surgery. Guide cannula (Plastics
One) were implanted into the brain targeting the substantia nigra (0°, -5.0mm
anterior-posterior, +2.1mm medial-lateral, -6.1mm dorsal-ventral) or ventral
pallidum (0°, -0.6mm anterior-posterior, +2.8mm medial-lateral, -6.3mm dorsalventral). Micro injectors (Plastics One) were inserted into the cannula projecting
+2.0mm to the target structure. 300 nL of rhodamine fluorescent latex
microspheres (Lumafluor) were injected into the target region. Animals recovered
for 2 weeks prior to use in experiments.
Electrophysiology: Whole-cell voltage-clamp recordings were made from
medium spiny neurons (MSNs) in the core of the nucleus accumbens (NAc).
MSNs retrogradely labeled with red beads that originated from either the SN or
VP were selected for recording. NMDAR currents were induced by pressure
ejection of NMDA and recorded at holding potential of -80 mV, -60 mV, -40 mV, 20 mV, 0 mV, 20 mV and 40 mV in the present of AMPAR antagonist CNQX (20
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µM) and GABAA receptor blocker picrotoxin (100 µM). NMDA (25 µM) was
pressure-ejected (5 psi, 300 ms) with a glass pipette (~1 µm tip opening). The I-V
curve of NMDAR currents showed strong inward rectification due to Mg2+ (1.3
mM) blockade at negative holding potentials.
RESULTS
To investigate the role of PACAP signaling in the reinstatement of drug
seeking, we employed a long-access cocaine self-administration paradigm. Once
rats acquired, maintained, and extinguished their cocaine intake and seeking,
they were subjected to a mock test. During the mock test, the rat was restrained
to acclimate them to the microinjection procedure they would encounter during
the reinstatement test. This was done to control for the stress of being restrained
and microinjected. On the reinstatement test day, rats were given a bilateral
infusion of vehicle (saline) or PACAP (100 pmol) into the NAcc paired with an
injection of cocaine (I.P.,10 mg/kg). A two-way repeated measure ANOVA was
used to determine differences in drug seeking (lever presses) during the cocaineprimed reinstatement test relative to a mock test (Figure 4-2 n=10/treatment). We
report a main effect of PACAP treatment (F1,18=13.03, p<0.05) and test
procedure (F1,18=45.89, p<0.05) with a significant interaction between these
variables (F1,18=13.82, p<0.05). Post-hoc tests revealed that 100 pmol PACAP
treatment significantly reduced drug seeking on the reinstatement test day
relative to 0 pmol (Tukey, p<0.05). These data demonstrate that PACAP
attenuates cocaine-primed reinstatement of drug seeking when injected into the
NAcc.
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Figure 4-2: PACAP
attenuates cocaineprimed reinstatement
when infused into the
NAcc. Data depicts
number of lever presses
during the reinstatement
test relative to a mock
injection test. Subjects
were infused with PACAP
or Saline bilaterally in the
NAcc in conjunction with a
10 mg/kg cocaine
injection I.P. *effect of
PACAP treatment relative
to vehicle p<0.05; # effect
of PACAP treatment
relative to mock p<0.05.

While PACAP attenuates drug seeking when exogenously applied to the
NAcc, the endogenous expression of PACAP, its source, and receptor
expression profile among astrocytes and neurons in the NAcc is unknown. To
test if PACAP is endogenous to the NAcc, we sampled extracellular fluid using
microdialysis and found PACAP to be present (Figure 4-3A). In order to ascertain
the endogenous source of PACAP in the NAcc, the mPFC to NAcc pathway was
labeled with a rhodamine retrograde tracer. This pathway in particular was
chosen due to the relevance of the PFC in executive function and drug seeking
(B. T. Chen et al., 2013). Fluorescent cells within the mPFC were extracted
using fluorescent-activated cell sorting (FACS) and PACAP mRNA was detected
in rhodamine positive but not rhodamine negative cells (Figure 4-3B). These
findings demonstrate that PACAP is an endogenous peptide in the NAcc that is
sourced by afferents from the mPFC.
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Figure 4-3. PACAP is
present in the NAcc and is
expressed in the mPFC to
NAcc pathway. A, Diagram
depicting microdialysis probe
placement in the NAcc with
PACAP concentration (pM).
B, PCR products from FACS
isolated rhodamine positive
mPFC to NAcc neurons and
rhodamine negative cell
populations. D1R/D2R,
dopamine 1 and 2 receptors.

Given the expression of PACAP in the NAcc we next investigated what the
molecular effects of PACAP signaling in the NAcc are. Currently, the PACAP
receptor expression profile and their functional impact in astrocytes and neurons
within the NAcc are unknown. First, we isolated NAcc astrocytes from the GFAP:
GFP-Lck transgenic rat via FACS so their PACAP receptor expression profile
could be determined (Figure 4-4A). PCR products for xCT, PAC1R and VPAC2
were detected with GFAP and GAPDH as positive controls and NeuN as a
negative control. Importantly, PACAP mRNA was not present in NAcc astrocytes
which suggests they are not a source of PACAP.
Next, the effect of PACAP signaling on glutamate transporters in
astrocytes was investigated. In the previous chapter we learned that PACAP
(100 nM) increases Sxc-dependent cystine-evoked glutamate release from
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Figure 4-4: PACAP signaling in astrocytes does not impact D-aspartate
uptake. A, PCR product from FACS isolated NAcc astrocytes. B, In vitro Daspartate clearance with and without 100 pmol PACAP applied for 30 minutes.
The Michaelis-Menten equation was used to estimate Km and Vmax.

striatal astrocytes. Here, we chose to investigate whether PACAP is influencing
astrocytic EAAT function by measuring D-aspartate uptake (Figure 4-4B). The
Michaelis-Menten equation was used to estimate changes in transport kinetics.
This model equation strongly fit clearance in both vehicle and PACAP treatment
groups (n=3-4/treatment, p<0.05) and explained 93% and 91% of the variability
in the data, respectively. Relative to vehicle, PACAP produced marginal changes
in D-aspartate transport kinetics (Km, 96.26 to 97.95 µM; Vmax, 58.90 to 63.17
µg/mg). Collectively, these data suggest that PACAP receptors are expressed by
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astrocytes in the NAcc and PACAP signaling does not appear to rapidly impact
on broad EAAT function.
Having established the presence of PACAP receptors in astrocytes and
the effect they have on Sxc and EAATs, we next investigated the impact of
PACAP signaling on NAcc efferents. First, we investigated PACAP receptor
expression in the two major efferents from the NAcc: the direct pathway to the
substantia nigra and the indirect pathway to the ventral pallidum. Both pathways
were labeled with rhodamine tracer and single cells were extracted. PCR
products for the dopamine receptors match established data (Kupchik et al.,
2015) serving as a positive control, and PACAP receptors appear to be
expressed in both pathways (Figure 4-5A,D). Intriguingly, the GluN2B subunit
appears to only be expressed in the direct pathway.
Given the presence of PACAP receptors in both pathways, we next tested
the physiological impact of PACAP signaling by measuring evoked EPSCs in
labeled efferent pathways. In the direct pathway, PACAP (100 nM) significantly
attenuated EPSC amplitude relative to baseline (Figure 4-5B; n=8; t13=2.91,
p<0.05) whereas in the indirect pathway, PACAP (100 nM) produced an increase
relative to baseline (Figure 4-5E; n=8; t21=2.59, p<0.05). Next, we investigated
the contribution of NMDAR current to the pathway specific effects of PACAP
signaling considering the expression of GluN2B is specific to the direct pathway.
Intriguingly, PACAP enhanced NMDAR mediated current even at hyperpolarized
holding potentials where Mg2+ block would otherwise prevent current
conductance in the direct (Figure 4-5C; n=8-10/treatment; p<0.05) but not
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Figure 4-5: PACAP signaling in NAcc efferents differentially tunes excitatory output.
A,D, PCR product from fluorescently labeled single cells from the direct and indirect pathway
respectively. B,E, Data depicts evoked EPSCs from direct and indirect pathway MSNs,
respectively, with and without PACAP treatment. C,F, IV curves depicting the effect of
PACAP on NMDA mediated currents on direct and indirect pathway MSNs respectively. Ttest, *p < 0.05; **p <0.01. Special thanks to Dr. Matt Hearing for collecting cells for A,D and
Dr. Qing-Song Liu for B,C,E,F.

indirect pathway (Figure 4-5F, n=7-8/treatment, p>0.05). These data
demonstrate that PACAP attenuates EPSCs but enhances NMDAR current
independent of holding potential in the direct pathway, but enhances EPSCs in
the indirect pathway while not impacting NMDAR currents.
Given that the effect of PACAP on EPSCs and NMDAR current is specific
to the direct pathway, we next chose to investigate if PACAP is interacting with
D1R or GluN2B containing NMDAR signaling since the expression profile of
these two receptors appears to be the only difference among the two pathways.
First, we determined if PACAP and D1R signaling are interacting to influence

112

Figure 4-6: PACAP
attenuates D1 receptor
agonist-primed
reinstatement. WT rats
were infused with
combinations of PACAP
and SKF, a D1 receptor
agonist during a
reinstatement test.
Cocaine was not
administered. *effect of
treatment relative to
control p<0.05; #effect of
PACAP relative to SKF
p<0.05.

reinstatement of drug seeking. Following a long-access cocaine selfadministration paradigm, WT rats were subjected to a microinjection of the D1R
agonist SKF (2 µg/side), PACAP (100 pmol), or a combination of both into the
NAcc (Figure 4-6). No cocaine was given during this reinstatement test. A oneway ANOVA revealed a significant effect of treatment (F3,36=12.437; p<0.05). A
Tukey test revealed a significant increase in drug seeking following SKF
treatment relative to the vehicle (DMSO) control (p<0.05). When PACAP was coadministered with SKF, drug seeking was significantly attenuated relative to SKF
alone (Tukey, p<0.05), but remained heightened relative to controls (Tukey,
p>0.05). These data suggest that D1R agonism is sufficient to increase drug
seeking which is partially blocked with the co-administration of PACAP which
suggests that dopamine and PACAP signaling are interacting to influence the
reinstatement of drug seeking.
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Figure 4-7: PACAP signaling requires Sxc and GluN2B to attenuate direct pathway
evoked EPSCs. A, Data depicts evoked EPSC amplitude from direct pathway MSNs cotreated with PACAP ± RO-25-6981, a use-dependent GluN2B antagonist. B, Evoked EPSC
amplitude from WT and MSxc rat direct pathway MSNs treated with and without PACAP
(100 nM). T-test, *p<0.05. Special thanks to Dr. Qing-Song Liu for conducting these
experiments.

The enhancement of NMDAR current while attenuating evoked EPSCs in
the direct pathway is suggestive of a net inhibitory effect of NMDARs on EPSCs.
Considering the pathway specificity of GluN2B we applied the GluN2B antagonist
RO 25-6981 (RO) to direct pathway neurons in conjunction with PACAP, which
revealed that GluN2B antagonism prevented PACAP from attenuating EPSCs
(Figure 4-7A; n=7; t11=2.97, p<0.05). Furthermore, the contribution of Sxc to this
effect was also tested on slices from MSxc rats which revealed that PACAP
could not attenuate EPSCs in the absence of Sxc (Figure 4-7B; n=7; t12=3.09,
p<0.01). These data reveal that PACAP attenuates evoked EPSCs and
enhances NMDAR mediated current in the direct but not indirect pathway and
these effects require GluN2B and Sxc.
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Figure 4-8: PACAP
dephosphorylates
GluA1 and GluN1 in the
NAcc. A,B,
Representative western
blots from NAcc tissue
samples from WT rats
injected with V, vehicle
or P, PACAP 100 pmol.
Data depicts ratio of
pT840/GluA1 and
pS897/GluN1
fluorescence intensity.
*p<0.05 Student’s T-test.

Given the attenuation of EPSCs in the direct pathway, we hypothesized
that this may be due to a change in AMPAR and NMDAR phosphorylation in the
NAcc. Two sites were investigated: T840 of GluA1 and S897 of GluN1. Given our
previous data showing a link between T840 and Sxc as well as the
aforementioned reduction by PACAP in hippocampal neurons (Toda & Huganir,
2015), we hypothesized that PACAP would decrease T840 in the NAcc. Indeed,
a t-test revealed a significant reduction in the ratio of GluA1 phosphorylation at
residue T840 to total GluA1 in rats microinjected with PACAP (100 pmol) into the
NAcc relative to vehicle controls (Figure 4-8A; pT840/GluA1, n=7-8/treatment, t13
= 2.178; p<0.05).
Regarding S897 of GluN1, which is important for trafficking NMDARs to
the synapse (B. Li et al., 2009), we hypothesized that PACAP signaling may be
moving NMDARs away from the synapse, putting them in a position to receive
Sxc-derived glutamate. A t-test revealed a significant reduction in the ratio of
GluN1 phosphorylation at residue S897 to total GluN1 as a result of PACAP
treatment (Figure 4-8B; pS897/GluN1, n=6-8/treatment, t12 = 2.386; p<0.05).

115

Figure 4-9: PACAP signaling requires Sxc and GluN2B to attenuate cocaineprimed reinstatement. WT and MSxc rats were infused with one of four
treatments in conjunction with a 10 mg/kg cocaine injection I.P. *effect relative to
vehicle p<0.05. #effect of treatment within genotype p<0.05.

These data suggest that PACAP influences GluA1 and GluN1 function in the
NAcc by changing the phosphorylation of key residues that dictate the
localization and or function of AMPARs and NMDARs. These biophysical
changes correlate well with the finding that PACAP produces a net inhibition of
EPSCs through a Sxc and GluN2B dependent mechanism.
Having demonstrated the necessity of GluN2B and Sxc for PACAP’s
ability to attenuate EPSCs in the direct pathway, we next tested their necessity in
regulating drug seeking behavior. WT and MSxc rats were subjected to a longaccess cocaine self-administration paradigm. During the reinstatement test, rats
were given a cocaine injection in conjunction with infusion of vehicle control,
PACAP, RO, or both into the NAcc (Figure 4-8). A two-way ANOVA revealed a
main effect of treatment (F3,52=5.646; p<0.05), no effect of genotype (F1,52=3.666;
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p>0.05), but a significant interaction between these variables (F3,52=10.148;
p<0.05). Post-hoc tests revealed PACAP attenuated reinstatement in WT (Tukey,
p<0.05) but not MSxc rats (Tukey, p>0.05) relative to vehicle. RO did not
significantly impact cocaine seeking in WT rats (Tukey, p>0.05), but did prevent
the attenuation of seeking when co-administered with PACAP (Tukey, p<0.05,
relative to PACAP alone; p>0.05, relative to vehicle). In MSxc rats, RO
attenuated drug seeking (Tukey, p<0.05, relative to vehicle) even in the presence
of PACAP (Tukey, p<0.05, relative to PACAP alone). These data suggest that
the effects of PACAP on cocaine seeking require Sxc and GluN2B, but there are
genotypic differences in the effect of RO.
DISCUSSION
The purpose of these experiments was to investigate how neuronal and astrocyte
signals are coordinated in the NAcc to alter network output and impact cognitive
control in drug seeking. These data demonstrate that the neuropeptide PACAP,
which is expressed by the mPFC to NAcc afferent, is able to attenuate drug
seeking via a multi-cell signaling mechanism that coordinates glutamate release
from astrocytes via Sxc and ligand binding of this signal in neurons by GluN2B
containing NMDARs. Remarkably, PACAP can precisely enhance NMDAR
current in the direct but not indirect pathway which results in a net inhibition of
evoked EPSCs. This phenomenon mimics a long-term depression-like
mechanism with the key features of astrocytic glutamate recruitment and
biophysical adaptation of neuronal NMDARs which collectively dephosphorylate
GluA1 and dampen excitatory output (Figure 4-10). In turn, the dampening of the
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Figure 4-10: Multi-cell
signaling mechanism
for PACAP signaling in
the NAcc. PACAP
sourced from the mPFC
signals through
astrocytes to enhance
Sxc function while also
signaling through
neurons to localize
NMDA receptors to the
extrasynaptic
compartment to receive
astrocytic glutamate.
This produces an
inhibitory effect on
GluA1 function in the
direct pathway which
attenuates cocaineprimed reinstatement.

direct pathway corresponds to reduced cocaine-primed reinstatement of drug
seeking.
The effect of acute PACAP application to astrocytes demonstrates rapid
increases in Sxc-mediated cystine-evoked glutamate release with no changes to
broad EAAT function as measured by D-aspartate uptake. Previous studies had
shown that the expression and function of Sxc, measured by cystine uptake, is
increased following 24-hour or greater application of PACAP (Kong et al., 2016;
Resch et al., 2014). Similarly, GLT-1 expression and function were upregulated
by PACAP following a 72-hour incubation (Figiel & Engele, 2000). Given the
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timescale of these changes, it is unlikely that these effects would be responsible
for the rapid behavioral effects of PACAP. Thus, more rapid assays consisting of
30-minute PACAP treatment were conducted. While not much is known about
post-translational modifications to xCT that produce changes in Sxc-dependent
glutamate release, PACAP signaling may produce a change in phosphorylation
status at one or more of the three putative regulatory sites S26, S185, or S481 to
enhance transport efficiency. Furthermore, the lack of changes in EAAT function
at 30 minutes suggests this specific effect may be restricted to long-term effects
of PACAP signaling. Collectively, the principle effect of PACAP signaling in
astrocytes is enhancement of glutamate release via Sxc.
The impact of PACAP signaling on the direct pathway is significant given
the established roles of striatal efferents in reward seeking. When D1R positive
neurons are stimulated optogenetically, cocaine-conditioned place preference
and cocaine induced locomotor activity is enhanced, with the opposite effect
occurring when D2R positive neurons are stimulated (Lobo et al., 2010). A major
unanswered question is how PACAP can selectively regulate the direct pathway,
given its receptors appear in both efferents. Preliminary evidence suggests that
the GluN2B subunit is specifically expressed by the direct pathway, which may
explain why this pathway is regulated by Sxc. Another major difference between
the two pathways according to our data is the expression of the dopamine
receptors D1R and D2R with the direct pathway exclusively expressing D1R and
the indirect pathway expressing a mix of D1R and D2R. Importantly, D1Rs have
been shown to enhance AMPAR mediated signaling through increased trafficking
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to the membrane (Chao, Ariano, Peterson, & Wolf, 2002; Gao, Sun, & Wolf,
2006). Since PACAP has a net inhibitory effect on AMPAR signaling, we were
curious about the potential interaction between PACAP and dopamine signaling
on cocaine seeking. Our data revealed that PACAP and D1R signaling interact to
regulate drug seeking with PACAP attenuating but not blocking D1R agonist
induced reinstatement.
Mechanistically, it is likely that PACAP and dopamine are interacting at the
AMPAR to gate excitatory output in the direct pathway. In support, application of
SKF to NAcc neurons increases GluA1 insertion into the membrane (Chao et al.,
2002). A follow up study, albeit in hippocampal neurons, demonstrated that
GluA1 was preferentially inserted into the extrasynaptic compartment and
subsequently laterally diffused into the synapse following NMDAR stimulation via
glycine (Gao et al., 2006). Within the context of our findings, this mechanism is
significant because the initial insertion of GluA1 into the extrasynaptic
compartment puts them in optimal position to be regulated by extrasynaptic
NMDAR. If the two-cell PACAP signaling mechanism is engaged, the newly
inserted D1R-dependent GluA1 would be dephosphorylated at T840 and thus
functionally dampened prior to their lateral diffusion into the synapse. In this way,
PACAP receptors and D1Rs are competing for control over AMPAR function and
ultimately control over direct pathway MSNs and reward seeking behavior.
Certainly, more research is required to understand the electrophysiological and
molecular factors that may be influencing this mechanism.
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The expression of PACAP in the PFC afferent to the NAcc is significant
finding for the addiction field and may explain why Sxc function in the NAcc is
reduced following drug intake. Disruption of the mPFC to NAcc pathway has
been suggested to be critical for the reinstatement of cocaine seeking. In
particular, long-term cocaine self-administration can broadly reduce the
excitability of PFC pyramidal neurons and when these neurons are
optogenetically stimulated, cocaine seeking is reduced (B. T. Chen et al., 2013).
One interpretation in line with our results is that neurons containing PACAP
projecting to the NAcc are being activated which is producing the reduction in
seeking. It could be that over the course of drug intake, the PFC is taken off-line
and PACAP is no longer being released into the NAcc from this afferent, which
causes Sxc function to decrease. By infusing PACAP into the NAcc during a
reinstatement test, we are rectifying this reduction. However, this does not rule
out the possibility that other glutamatergic NAcc afferents such as from the
basolateral amygdala which are also critical for cocaine seeking (B. R. Lee et al.,
2013) may contain PACAP. Future research should be aimed at determining
whether dysregulation in PACAP production or release from NAcc afferents is
predictive of the propensity for relapse.
While speculative, PACAP may encode qualitative information about
incoming stimuli; signaling to local astrocytes that the incoming stimulus
information is strong and requires astrocytes to help in processing and
disseminating this information to the network. Importantly, peptides are typically
released from neurons under different circumstances relative to small

121
neurotransmitters, including specific patterns of firing or long durations of activity
(Cropper, Jing, Vilim, & Weiss, 2018). Thus, the information coming from the
mPFC or possibly other NAcc afferents is likely specific to the environmental
circumstances and PACAP is released to signal to astrocytes that they are
needed to process this information. Given the actions of PACAP, it may encode
negative feedback about the probability of a rewarding outcome, which may be
why it potently blocks reinstatement.
The biophysical adaptations of GluA1 and GluN1 produced by PACAP are
consistent with and expand on previously established findings. PACAP signaling
in hippocampal neurons results in a reduction in pT840/GluA1. Importantly, this
phenomenon requires NMDAR activation (Toda & Huganir, 2015). We found that
PACAP in the NAcc can produce the same reduction in pT840 which coincided
with enhancement of NMDAR currents and an attenuation of evoked EPSCs in
the direct but not indirect pathway. Intriguingly, PACAP was able to enhance
NMDAR currents even at holding potentials where Mg2+ block would otherwise
be present. One interpretation of this is that PACAP is altering NMDAR to make
them resistant to Mg2+ allowing them to be more rapid in their signal transduction
capabilities rather than coincidence detectors that require sufficient antecedent
AMPAR mediated depolarization. In support of this theory, protein kinase C
(PKC) reduces Mg2+ block of NMDARs (L. Chen & Huang, 1992) and PACAP
activates PKC (Macdonald et al., 2005). The reduction in Mg2+ block allows any
neuron in the network that contains these modified NMDARs to be disengaged in
a synchronized fashion independent of activity state, which could be argued as
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an incredibly powerful and efficient inhibitory signal. Despite this, a lingering
question remains; how is PACAP able to do this in a pathway specific fashion
even though its receptors appear to be expressed by both efferents?
One interpretation of the pathway specific effects of PACAP is that only
the astrocytes that are interacting with the direct pathway contain Sxc and
therefore PACAP and Sxc can only effectively alter that network. On the other
hand, the NMDAR encoding Sxc-derived glutamate may only be expressed by
the direct pathway. Preliminary evidence suggests that only the direct pathway
contains the GluN2B subunit. This is a controversial claim, which will require
more research to fully investigate, but the findings that GluN2B is necessary for
the effects of PACAP on EPSC amplitude in the direct pathway and consequently
drug seeking behavior support this interpretation. Furthermore, there was
evidence that PACAP enhances EPSCs in the indirect pathway. It is not clear
whether Sxc is involved in this regulation. The enhancement of the indirect
pathway could be due to PACAP signaling through its receptors on these
neurons to increase phosphorylation of residue S845 of GluA1 which has been
shown to enhance the synaptic retention and ion conductance of AMPARs
(Diering, Heo, Hussain, Liu, & Huganir, 2016; Toda & Huganir, 2015). If GluN2B
is not expressed by the indirect pathway, T840 of GluA1 is unlikely to be
impacted which places AMPARs in an enhanced rather than inhibited state
following PACAP treatment.
The finding that pS897/GluN1 is dephosphorylated because of PACAP
signaling is novel and suggests that neural signals can control glutamate
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receptor localization. When pS897/GluN1 is mutated into a phospho-resistant
residue, the expression of GluN1 and GluA1 significantly decreases in
hippocampal synapses which coincides with an impairment in LTP induction (B.
Li et al., 2009). Since PACAP is dephosphorylating pS897/GluN1, it should
reduce synaptic localization of GluN1. It is unclear if these receptors are
internalized or lateralized into the extrasynaptic compartment, but in either
scenario, extrasynaptic NMDAR would likely be dominant. Given that
pT840/GluA1 is a pro-synaptic enrichment marker regulated by NMDAR
activation, the net outcome of this extrasynaptic NMDAR signal is likely
dephosphorylation of pT840/GluA1 which produces an LTD-like effect. Given
PACAP’s actions on NMDAR mediated and evoked EPSCs, it is likely
destabilizing synaptic glutamate receptors in a pathway specific manner thus
reducing their ability to encode synaptic glutamate.
The ability of astrocytes to potentiate and depress neural networks is
emerging as a fundamental principle of brain function (Martin et al., 2015). Initial
investigations into this phenomenon revealed the role of D-serine release from
astrocytes, an NMDAR co-agonist, in the potentiation of synapses in the
hippocampus (Henneberger, Papouin, Oliet, & Rusakov, 2010). This release
mechanism has been demonstrated to be sensitive to intracellular Ca2+ and
dependent on vesicular fusion. However, the causative factors or receptors that
drive this mechanism remain unclear, but theoretically any factor that can
produce broad changes in Ca2+ within an astrocyte could be involved. PACAP
signaling through its Gq coupled receptors could theoretically trigger Ca2+
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transients in astrocytes, but other factors we previously explored such as
endocannabinoids could also engage this mechanism. Future experiments
should be aimed at discerning the intracellular signaling cascades triggered by
PACAP signaling and whether they are sufficient to induce release of nonglutamatergic gliotransmitters that modify neural networks.
The reinstatement data from WT and MSxc rats reveals how GluN2B can
have different effects on cocaine seeking depending on Sxc activity. In WT rats
treated with cocaine and RO, which represents basal Sxc activity, there was no
significant effect on cocaine seeking relative to vehicle. With a PACAP treatment,
which represents enhanced Sxc function, cocaine seeking is reduced, but if RO
is co-administered, this reduction is blocked. Conversely, in MSxc rats, which
represents an absence of Sxc activity, cocaine with RO alone is sufficient to
attenuate cocaine seeking and PACAP is unable to alter cocaine seeking with
RO present. This suggests the following: when Sxc activity is unaltered, GluN2B
has minimal impact on cocaine seeking. When Sxc activity is enhanced, GluN2B
is involved in attenuating cocaine seeking and when Sxc activity is absent,
GluN2B drives drug seeking. From a therapeutic perspective, this highlights the
difficulty in targeting receptors to treat disorders; the efficacy and behavioral
outcome of the drug may be different depending on, in this instance, the status of
glutamate release from astrocytes. Given the multitude of biological variables
that could impact drug efficacy such as time of day, bioavailability, and sex, it is
not surprising that unveiling effective therapies for addiction relapse has been
difficult.
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Collectively, these data demonstrate that PACAP signals through
astrocytes and neurons to coordinate astrocytic release and neuronal reception
of glutamate. This dual-cell signaling mechanism attenuates excitatory output in
the direct but not indirect pathway and attenuates cocaine-primed reinstatement
of drug seeking which requires Sxc and GluN2B. It is possible that PACAP is
encoding stimulus information from the mPFC that signals to astrocytes that they
are needed to help process this information and actualize it into a functional
output through regulating specific NAcc efferents. From a therapeutic
perspective, PACAP has revealed the significance of Sxc and GluN2B in
regulating drug seeking behavior. Given the emerging literature on Sxc-targeting
compounds and the recent approval of NMDAR targeting drugs such as
Esketamine for severe depression by the FDA (Gould, Zarate, & Thompson,
2019), it is possible that we have begun to unveil novel therapeutic targets as a
result of an increased understanding of intercellular communication involving
astrocytes. However, our behavioral data reveals that more research will need to
be done to understand how manipulating GluN2B signaling can have varying
outcomes on cocaine seeking. Ultimately, these findings might have therapeutic
implications for not only substance abuse, but other neuropsychiatric diseases.
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CHAPTER V:
PERSPECTIVES ON THE IMPORTANCE OF SYSTEM XCTO INTERCELLULAR COMMUNICATION AND
COGNITIVE PROCESSING

The goal of these studies was to investigate the novel idea that the
evolutionary expansion of signaling complexity between brain cells contributed to
evolutionary gains in cognitive ability. Progress in this area has the potential to
transform efforts to treat cognitive dysfunction that is present in an array of CNS
disorders. The primary benefit of the findings reported here was to illustrate the
relevance of signaling mechanisms in astrocytes, which are among the most
abundant cells in the human brain. Specifically, we provide novel support for the
hypothesis that evolutionarily-new glutamate signaling mechanisms expressed
by astrocytes are selectively required for complex forms of cognition.
Our study of astrocyte signaling focused on the characterization of the
cysteine-glutamate antiporter Sxc. We were interested in studying Sxc function
from the molecular to the behavioral level. As discussed below, our data
provides preliminary insights into how Sxc has been integrated into neuronal and
tripartite signaling mechanisms (Figure 5-1) to produce complex regulation of
behavioral control. However, the ultimate significance of these studies will be
determined by the future lines of research triggered by our findings.
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Figure 5-1: How PACAP and Sxc fit into the model of tripartite synapse function. The
major advancements of this work are highlighted by the inclusion of PACAP, its receptors,
and the net outcome of the intercellular communication produced by its signaling. PACAP is
released by afferents from the mPFC, and possibly other afferents and is received by
receptors expressed by neurons and astrocytes. Within astrocytes, PACAP enhances Sxcmediated glutamate release. In neurons, PACAP likely facilitates dephosphorylation of
GluN1 at S897 which concentrates NMDARs in the extrasynaptic compartment. Here,
GluN2B containing NMDARs encode glutamate released by Sxc and display enhanced
conductance even during hyperpolarized potentials. The significance of this phenomenon is
that antecedent depolarization via AMPARs is not required to remove Mg 2+ block from the
NMDAR which allows Sxc to activate the NMDAR of silent neurons. Activation of GluN2B
inhibits evoked EPSCs, likely through the dephosphorylation of GluA1 at T840. This cellular
and molecular mechanism specifically attenuates the direct pathway from the NAcc to the
substantia nigra pars compacta (SNpc) which effectively gates the ability for this pathway to
elicit a behavioral response.

The Significance of Sxc to the Tripartite
The significance of glutamate release from astrocytes to signaling within
the tripartite is evidenced by our findings that Sxc in the NAcc influences
neuronal (e.g., ionotropic glutamate receptors) and astrocytic (glutamate
transporters) signaling mechanisms, and that it in turn is regulated by multiple
neuronal mechanisms (e.g. PACAP, endocannabinoids). In support, a loss of Sxc
impaired astrocytic EAAT function, which would likely produce an increase in
synaptic (and extrasynaptic) concentrations of extracellular glutamate.
Additionally, a loss of Sxc does not appear to impact presynaptic release of
glutamate, which was surprising given a previously established link between the
two (Baker et al., 2002). However, Sxc activity was found to contribute to the
tuning of glutamate signaling within the synapse by negatively regulating AMPAR
function, an effect that we and others indicate is likely mediated by extrasynaptic
NMDARs (Delgado et al., 2007). Regulation of AMPAR function likely involves
the regulation the phosphorylation of GluA1, specifically residue GluA1 T840,
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that has been shown to influence AMPAR clustering in the synapse (Williams &
Featherstone, 2014). This is an important finding because the regulation of
synaptic transmission by numerous signaling mechanisms, including dopamine
transmission (Chao et al., 2002; Gao et al., 2006), may involve the regulation of
AMPARs. Hence, these receptors appear to be a site of convergence for highly
disparate signaling mechanisms within the tripartite.
Much of what we learned about the molecular and cellular roles for Sxc
involved its actions in the NAcc. We found that Sxc contributes to the gating of
NAcc efferent pathways in a manner that regulates behavior. In particular, a
surprising finding was the apparent involvement of Sxc in suppressing the activity
of the direct pathway (NAcc-SN) although there was not a clear effect of loss of
Sxc on the second major efferent, the indirect pathway (NACC-VP). Given that
the direct pathway is canonically viewed to drive motivated behavior (BrombergMartin et al., 2010; Lobo et al., 2010), the regulation of this pathway by Sxc
suggests that astrocytes contribute to local processing of incoming information to
modify behavioral output. Presumably, Sxc activity in other structures, such as
the prefrontal cortex, also functions to provide complex, potentially pathwayspecific gating of afferent and/or efferent outputs in a manner that facilitates
cognition.
A critical issue we examined was how Sxc-dependent astrocyte to neuron
signaling is regulated. While astrocytes are increasingly implicated in the
regulation of neural circuits, there is a need to understand how glutamate release
from astrocytes is coordinated with neuron to neuron signals. First, we examined
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the regulation of Sxc by mechanisms often linked to the control of neuron-neuron
signaling by determining the capacity of corticosterone, endocannabinoids, and
PACAP to produce rapid changes in Sxc activity. In part, these mechanisms
were selected because they reflect control provided by presynaptic neurons,
postsynaptic neurons, and circulating hormones. We found each of these
signaling mechanisms to exert rapid regulation of Sxc activity. The ability for
these factors to influence Sxc suggests that even though Sxc is astrocytic and
evolutionarily-new, it has become integrated into the tripartite.
An exciting question that remains to be answered is at what point on the
evolutionary timescale did neural and hormonal factors develop the ability to
influence Sxc function. To address this question, we searched for putative
consensus phosphorylation sequences on xCT, and then mapped their
appearance on the evolution of vertebrates to find three conserved regulatory
sites, S26, S185, and S481. S481 is interesting considering this site exists in
mammals but no other vertebrates. In contrast, S26 is only expressed in some
birds and mammals. Because these serine residues are targeted by MSK1,
which is downstream of glucocorticoid, PACAP, and MAP kinase signaling (Beck
et al., 2013; Butcher et al., 2005), an important question that remains is how
PACAP and corticosterone signaling interact to influence the phosphorylation of
these residues and consequently change Sxc function. Furthermore, why certain
organisms have these regulatory sites versus others needs to be answered as it
will help illuminate their biological significance. Given these findings, Sxc has
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been evolving in vertebrates to engrain itself into the processing of information
provided by neurons and the hormonal milieu.
The Role of PACAP in Shaping Sxc-Mediated Astrocyte to Neuron Signaling
The regulation of Sxc by PACAP was especially intriguing to us largely
due to the profound effects that this neuropeptide has been shown to produce on
glutamate transporters and receptors (Figiel & Engele, 2000; Kong et al., 2016;
Resch et al., 2014; Toda & Huganir, 2015). As a result, we chose to investigate
this Sxc-regulatory mechanism in greater detail. We found PACAP to be
expressed by mPFC-NAcc neurons and is present in the interstitial space of the
NAcc. Collectively, these are the first data to implicate PACAP as a neuropeptide
in NAc afferents. The distribution of PACAP receptors provided interesting
insights into its function. We found that PACAP appears to enable, and possibly
control the impact, of Sxc-mediated astrocyte to neuron signaling by acting on
both astrocytes and potentially receptive neurons.
PACAP receptors were detected in NAcc astrocytes, which likely explains
how this neuropeptide is able to exert rapid regulation of cystine-evoked
glutamate release by Sxc. To our surprise, the capacity of PACAP to regulate
astrocytic glutamate mechanisms did not extend to rapid control of EAAT
function as measured by D-aspartate uptake. However, this does not rule out the
possibility that PACAP may engage glutamate transporters other than Sxc and
EAATs to regulate extracellular glutamate.
Neuronal PACAP receptors may define the nature or impact of incoming
signals from astrocytes. First, we learned that PACAP dephosphorylates GluN1
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at residue S897. This is interesting because this site has been shown to promote
diffusion of the NMDA receptor out of the synapse (B. Li et al., 2009), where it
may be exposed to Sxc-released glutamate. Second, neuronal PACAP signaling
appears to relieve NMDAR blockade by Mg2+. This unexpected finding may add
to a limited body of work indicating that Mg2+ blockade is a powerful form of
NMDAR regulation by intracellular signaling pathways (L. Chen & Huang, 1992;
Hahn, Wang, & Margeta, 2015; Moriguchi et al., 2007; Tyszkiewicz, Gu, Wang,
Cai, & Yan, 2004). In the absence of PACAP-induced removal of Mg2+
blockade, Sxc-activation is unlikely to stimulate extrasynaptic NMDA receptors.
Instead, Sxc regulation of neuronal function is traditionally linked to metabotropic
receptors (M. M. Moran et al., 2005; Moussawi et al., 2011). Hence, the question
becomes, how might activation of extrasynaptic NMDARs produce unique
changes to neuronal activity? Extrasynaptic NMDARs have been shown to inhibit
synaptic transmission by altering the phosphorylation of multiple residues of the
AMPAR subunit GluA1, (Delgado et al., 2007; Toda & Huganir, 2015). Consistent
with this, we observed PACAP-induced suppression of synaptic transmission,
which was dependent on both Sxc and GluN2B-expressing NMDARs.
The attenuation of synaptic activity by PACAP-mediated Sxc to NMDA
signaling was pathway specific, which raises the possibility that PACAP also
determines which cells are impacted by Sxc-mediated astrocyte to neuron
signaling. In support, we observed PACAP-induced regulation of NMDA receptor
function and synaptic activity in the direct but not the indirect pathway. Similarly,
we observed pathway-specific differences in expression of the various PACAP
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receptors and in the expression of GluN2B. While these preliminary
observations require further study, these findings provide a potential mechanism
illustrating how astrocytes can produce cell- and pathway-specific regulation of
synaptic activity even when maintaining tonic glutamate concentrations
throughout the diffuse, interstitial space.
In addition to discrete signaling mechanisms such as PACAP, the complexity of
the tripartite may contain forces regulating glutamate receptor activation. For
example, we have long assumed that extrasynaptic, interstitial concentrations of
glutamate were relatively homogenous, and therefore displayed a volume
transmitter type of signaling. This information has been used to form predictions
about extracellular glutamate concentrations, receptor affinity for glutamate, and
patterns of receptor activation. To the extent that we considered areas of
extracellular glutamate to display spatial-dependent differences in concentration,
the assumption was that equilibrium in glutamate concentration was solely due to
a diffusion pattern determined by concentration gradients. However, modern
findings in neuroscience indicate that it may time to reexamine what we think we
know.
Is Sxc-NMDAR Signaling Impacted by the Structure of the Extrasynaptic Space?
Is glutamate movement in the interstitial space solely determined by
glutamate concentration? This is often assumed to be the case in the
extrasynaptic space. Specifically, we have long assumed that astrocytes
maintain a near homogenous concentration of glutamate that reflects the relative
affinity of glutamate receptors. Theoretically, a much more efficient and effective
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mode of intercellular signaling would be a system in which the release site of
glutamate was targeted toward the receptive site (e.g., the receptor populations)
akin to the synapse. In the context of our findings, the question is whether
PACAP enables a very specific signaling axis between astrocytes and neurons
by the precise targeting of NMDARs. A critical advantage of this system would be
the capacity to create multiple, functionally distinct, signaling microdomains that
could be more efficiently maintained due to the reduced need of extracellular
glutamate molecules. The reduction in the number of glutamate molecules would
be due to the reduction in the extracellular space requiring a set concentration of
glutamate that would be capable of activating the receptor.
The extracellular matrix, which represents the structural foundation of
neural circuits, is gaining recognition for its role in compartmentalizing the brain
to create the types of signaling efficiencies described above (Dityatev et al.,
2010). An important question is whether the extracellular matrix physically links
astrocytic Sxc with neuronal glutamate receptors that are trafficked into the
appropriate zone in a cell- and signal- specific manner. Again, this would mimic
vesicular release machinery, which adheres to adjacent post-synaptic density
proteins (Christopherson et al., 2005; Eroglu et al., 2009; Hata et al., 1993; Kania
& Klein, 2016; Kucukdereli et al., 2011).
Assessing the likelihood that Sxc interacts with the extracellular matrix and
possibly other transmembrane cellular adhesion proteins on neurons to localize
to adjacent to NMDARs requires insight into the crystalline structure of the Sxc
subunits. Importantly, there are two subunits of Sxc, the light chain xCT and
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heavy chain 4F2hc (or designated as CD98), which is also essential for the
expression of the light chain in the membrane. CD98 has many light chain
partners (Mastroberardino et al., 1998) interacting across three domains:
cytoplasmic, transmembrane, and extracellular all with their unique functions.
The cytoplasmic and transmembrane domains of CD98 interact with cell
adhesion proteins such as integrins to facilitate their binding to their extracellular
ligands (Fenczik et al., 2001). Integrins have a number of different extracellular
ligands such as components of the basement membrane of the extracellular
matrix (collagens, tenascins, laminins etc.) and can also facilitate direct cell-cell
interactions (Humphries, Byron, & Humphries, 2006). The extracellular domain of
CD98 is important for facilitating amino acid transport through the light chain, i.e.
xCT, due to the covalent interaction of cysteines within this domain with the light
chain (Fenczik et al., 2001). Furthermore, CD98 has been well studied by cancer
researchers due to its ability to interact with cellular adhesion proteins such as
integrins, which facilitate the migration of cancer cells through the extracellular
parenchyma (Feral et al., 2005). However, this phenomenon is not limited to
cancer cells, as a similar phenomenon is observed in epithelial cells (Cai et al.,
2005).
Likewise, NMDARs also interact with integrins. The interaction between
integrins and the extracellular matrix or potentially adjacent cellular ligands
increase the amplitude of NMDAR currents (Lin, Arai, Lynch, & Gall, 2003).
These findings demonstrate that the function of Sxc and NMDARs are impacted
by the cellular adhesion protein integrin and that perhaps, Sxc and NMDARs are
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interacting with the same ligands within the extracellular matrix. A key experiment
would then be to determine if Sxc and NMDARs co-localize or coimmunoprecipitate via their association with integrins. If so, it would suggest that
glutamate signaling within the extrasynaptic compartment follows similar design
principles to the synaptic cleft by utilizing transcellular protein bridges that
facilitate high-fidelity intracellular communication between release mechanisms
and receptors.
As introduced above, the extracellular matrix may permit the creation and
maintenance of discrete signaling zones. Another critical factor in the formation
of discrete signaling zones is the volume of the interstitial space, which is
determined by the physical proximity of cellular membranes (often astrocyte and
neuronal membranes). Notably, the volume of the interstitial space is regulated
by neuronal activity, in part by influencing astrocyte swelling. In support, neuronal
depolarization causes an elevation in extracellular K+ which triggers uptake into
adjacent astrocytes through inwardly rectifying K+ channels and Na+/K+
ATPase. This process produces an osmotic gradient in astrocytes that drives
water influx through aquaporins causing the astrocytes to swell and thus reduce
extrasynaptic volume (Hubel & Ullah, 2016). Additionally, glutamate released by
neurons drive uptake though astrocytic transporters e.g. GLT-1 which cotransports Na+. This also triggers swelling in the astrocyte and consequently a
reduction in the extrasynaptic volume (MacAulay, Hamann, & Zeuthen, 2004),
which can produce an anisotropic diffusion pattern i.e. a biased directionality to
the flow of glutamate in the extracellular space. Such cellular barriers reduce the
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mobility of glutamate by producing “dead zones” in the extracellular space that
impede the flow of signaling molecules and bias glutamate access to specific
zones within the extracellular domain (Vargová & Syková, 2014). Given these
findings, synaptic glutamate (or glutamate released into extrasynaptic
microdomains) could be compartmentalized from synaptic glutamate via cellular
swelling. These ideas will require further research, but they provide a clear
demonstration that a more thorough understanding of the complexity within the
tripartite may lead to highly novel approaches to understand glutamate signaling
in health and disease.
The Significance of Sxc to Cognition
Our studies provided multiple examples of cognitive dysfunction following
a loss of Sxc. We found that MSxc rats more readily engage with a reward-paired
CS (CS+) during the PCA paradigm. Intriguingly, approach toward CS+ was
maintained even if this behavior was punished by withholding reward delivery.
This was the first hint that MSxc rats displayed cognitive deficits, which was
illustrated by an inability to adapt their behavior in response to changing reward
contingencies and is considered a principle executive function (Diamond, 2013).
This type of executive dysfunction was also observed during the attentional set
shifting paradigm, whereby MSxc rats took significantly more trials relative to WT
rats to adapt a new behavioral strategy to obtain rewards in a maze. Likewise, in
Kamin fear blocking, attentional gating of extraneous stimuli was disrupted in
MSxc rats which made them more likely to freeze to stimuli that were otherwise
weak predictors of danger. These maladaptive associative learning and inflexible
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perseverative patterns of behavior seen in MSxc rats manifested as an increased
vulnerability to relapse of cocaine seeking.
The role of Sxc in cognitive processing appears to depend on the complexity of
cognition or behavior. As noted above, a loss of Sxc impacted cocaine
reinstatement, reversal learning, extra-dimensional shift, goal-tracking, and
Kamin blocking. In contrast, it did not alter the formation of simple Pavlovian or
operant associations, novelty-induced locomotion, cocaine self-administration,
extinction, or fear conditioning. In comparing behaviors impacted versus those
that are unaltered, it appears that behaviors impacted by a loss of Sxc are
generally deemed to be more complex and involve top-down processing. These
data are similar to the pattern of behavior observed by disruption of
evolutionarily-new components of the synaptic proteome (Nithianantharajah et
al., 2013). Collectively, these findings lend support to the idea that evolutionarily
novel biological mechanisms, including those expressed by astrocytes, may
provide novel opportunities to understand and treat cognitive dysfunction.
Can a Phylogenetic Strategy Expedite the Development of Effective CNS
Therapeutics?
As is the case for most forms of human disease, a key therapeutic
breakthrough may not be realized until the molecular basis of the pathological
process is understood to the point of being able to develop effective and safe
treatments. For CNS disorders, this is exceedingly challenging. Uncovering the
basis of cognition is hindered by the exceptional complexity of the brain, which
makes developing therapies that avoid producing significant side effects
challenging. For example, the prior sections provide a sense of the complexity
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that has been revealed within a single tripartite; presumably, this is far from
complete. Regardless, scaling up the complexity inherent in a single tripartite to
account for the billions of cells and trillions of signaling microdomains provides a
useful perspective of the challenge posed by the human brain through
reductionist approaches. This has led some investigators to search for a
different approach to understanding and treating cognitive dysfunction.
One effective strategy may be to leverage phylogenetics, the study of the
evolutionary relationships among species at the systemic and molecular level (Z.
Yang & Rannala, 2012). From this we may be able to discriminate foundational
neural mechanisms from those that may be selectively involved in enabling
phylogenetic gains in cognition. To implement this approach, genes that were
recently acquired or currently evolving within the vertebrates can be manipulated
to determine their biological significance (E. J. Vallender, 2008). For example,
adaptations in the intracellular domain of the GluN2 subunit of NMDA receptors
expanded the complexity of its downstream signaling partners, which may
explain the expansion of cognitive ability in vertebrates versus invertebrates (T.
J. Ryan, Emes, Grant, & Komiyama, 2008).
Similarly, the four paralogues of Dlg/membrane-associated guanylate
kinase scaffolding protein in the synapse have evolved in vertebrates to have
discrete roles in cognitive processing. For example, Dlg1/4 share the greatest
sequence homology with the ancestral invertebrate Dlg and when knocked out in
mice can produce unviable mice or significant deficits in basic learning whereas
Dlg2/3 knockouts have a more unique sequence relative to ancestral Dlg
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resulting in no deficits in basic learning but only cognitive deficits during complex
tasks (S. G. Grant, 2016). This suggests that phylogenetics can be used to
isolate biological components and categorize them based on their involvement in
fundamental or adaptive brain functions. Identifying these adaptations will be
critical if we are to understand the molecular origins of what separates our
cognitive ability from other organisms, and may lead to rapid gains in our ability
to treat cognitive dysfunction.
Closing Remarks
Substance abuse, depression, anxiety, cancer, type 2 diabetes,
cardiovascular disease, obesity, and schizophrenia represent the most
debilitating diseases in the modern world. To tackle this disease burden from a
utilitarian perspective and do the greatest good for the greatest number of people
possible, we need to approach treating disease by tackling the common
underlying symptoms. The common symptom in the above disorders is cognitive
dysfunction (Cannon et al., 2017; Harrison & Wefel, 2018; He et al., 2018; Jones
et al., 1992; Lange et al., 2017; Millan et al., 2012; P. M. Moran et al., 2008; Rock
et al., 2014; Y. Yang et al., 2018). Each of these disease states carry an inherent
inability for the patient to appropriately adapt their behavior in response to their
internal thoughts and emotions and external environmental circumstances which
produces an overall reduction in their biological fitness. Solving this problem will
take a lot of work, and this document represents a paradigm shift in how we can
investigate novel therapeutic avenues. Using principles from evolutionary biology
and expanding beyond the neuron and synapse, we can hopefully more easily
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determine what the molecular basis of cognition in humans is and thus be more
effective in treating dysfunctional states. While this work is far from complete, it
sets the foundation for research into other mechanisms expressed by astrocytes
that may also contribute to cognitive disorders. While Sxc serves as an intriguing
therapeutic target a concession can be made that Sxc and more broadly
astrocytes may not be the solution, but it serves as a well needed paradigm shift
in how we view brain function and how to treat its most debilitating diseases.
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